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Introduction 1
1. Introduction 
Pulmonary hypertension (PH), a chronic disorder of the pulmonary 
vasculature, is characterized by progressive elevation in pulmonary artery 
pressure and the ultimate development of right heart failure and death (1). It is a 
devastating disease that drastically limits physical capacity and seriously reduces 
life expectancy. On average, without treatment, patients had a median life 
expectancy of less than 2.8 years post diagnosis (2). However, the true incidence 
of PH is rare, 1–2/million/year and approximately 10% appear to be familial (3). 
Interestingly, a preponderance of females among PH patients was noted with a 
ratio of female to male varying between 1.7 and 3.5:1(4).  
Pulmonary hypertension (PH) was first described over 100 years ago by Ernst 
von Romberg, a distinguished German physician and clinical scientist, in a 
patient with right-heart failure whose necropsy showed no obvious reason for 
pulmonary arteriosclerosis and diagnosed as "sclerosis" of the pulmonary 
arteries. In 1901, Ayerza noted the profound cyanosis associated with this 
disorder, and described the disorder as "cardiacos negros", but it was Dresdale 
and coworkers who first used the term primary pulmonary hypertension (PPH) 
and subsequently demonstrated the involvement of pulmonary vasoconstriction 
in the pathogenesis of PPH (5). Interest in so-called PPH was excited in 1967–
1972 by an epidemic that was attributed to the ingestion of an appetite 
suppressant, aminorex fumarate (6). This epidemic “Wake-up call” to the 
scientific community prompted the first WHO sponsored symposium, monograph 
on diagnosis and treatment and a substantial progress in understanding the 
pathogenesis of this disorder.  
 
1.1 Definition & Classification 
Pulmonary hypertension is defined as a sustained elevation of pulmonary arterial 
pressure to more than 25 mm Hg at rest or to more than 30 mm Hg with 
exercise, with a mean pulmonary-capillary wedge pressure and left ventricular 
end-diastolic pressure of less than 15 mm Hg. In the past, based on etiology, 
pulmonary hypertensive was divided into two categories (7). 
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i) Primary pulmonary hypertension (PPH): describes PH without a demonstrable 
etiology.  
ii) Secondary pulmonary hypertension (SPH): describes PH that results from a 
coexisting condition known to be complicated by pulmonary hypertension.  
However, due to similar histopathological features and treatment responses 
among these two groups of patients, in 1998, during the Second World 
Symposium on PH held in Evian, France, a new clinical classification of PH was 
proposed (8). 
The Evian classification consisted of five categories and had focused mainly on 
the basis of mechanisms, rather than the associated conditions: 1) pulmonary 
arterial hypertension (PAH), 2) pulmonary venous hypertension (PVH), 3) PH 
associated with disorders of the respiratory system or hypoxemia, 4) PH caused 
by thrombotic or embolic diseases, and 5) PH caused by diseases affecting the 
pulmonary vasculature. PAH has been further divided into idiopathic pulmonary 
arterial hypertension (IPAH) and, when supported by genetic evidence, familial 
pulmonary arterial hypertension (FPAH). Like wise, within each category are 
subsets that reflect diverse causes and sites of injury. This classification served 
as a useful guide to the clinician in organizing the evaluation of a patient with PH 
and developing a treatment plan.  
Recently, a revised clinical classification was proposed at Venice conference in 
2003 (1) (Table 1, Page 3). This classification has preserved the structure and 
spirit of the Evian classification. However, it includes changes that reflect recent 
advances in the understanding and management of PH and uses consistent 
terminology and defines pulmonary hypertension more precisely than previous 
versions.  
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Table 1: Clinical Classification of Pulmonary hypertension 
 
 
 
 1. Pulmonary arterial hypertension (PAH)  
 1.1. Idiopathic (IPAH)  
 1.2. Familial (FPAH)  
 1.3. Associated with (APAH):  
 1.3.1. Collagen vascular disease  
 1.3.2. Congenital systemic-to-pulmonary shunts**  
 1.3.3. Portal hypertension  
 1.3.4. HIV infection  
 1.3.5. Drugs and toxins  
 1.3.6. Other (thyroid disorders, glycogen storage disease, Gaucher  
           disease, hereditary hemorrhagic telangiectasia,  
           hemoglobinopathies, myeloproliferative disorders, splenectomy)  
 1.4. Associated with significant venous or capillary involvement  
 1.4.1. Pulmonary veno-occlusive disease (PVOD)  
 1.4.2. Pulmonary capillary hemangiomatosis (PCH)  
 1.5. Persistent pulmonary hypertension of the newborn  
 
 2. Pulmonary hypertension with left heart disease  
 2.1. Left-sided atrial or ventricular heart disease  
 2.2. Left-sided valvular heart disease  
 
 3. Pulmonary hypertension associated with lung diseases and/or  
               hypoxemia  
 3.1. Chronic obstructive pulmonary disease  
 3.2. Interstitial lung disease  
 3.3. Sleep-disordered breathing  
 3.4. Alveolar hypoventilation disorders  
 3.5. Chronic exposure to high altitude  
 3.6. Developmental abnormalities  
 
 4. Pulmonary hypertension due to chronic thrombotic and/or embolic
               disease  
 4.1. Thromboembolic obstruction of proximal pulmonary arteries  
 4.2. Thromboembolic obstruction of distal pulmonary arteries  
 4.3. Non-thrombotic pulmonary embolism (tumor, parasites, foreign material)  
 
 5. Miscellaneous  
 Sarcoidosis, histiocytosis X, lymphangiomatosis, compression of  
  pulmonary vessels (adenopathy, tumor, fibrosing mediastinitis) 
 
 
 
(Revised classification of pulmonary hypertension (Venice 2003) from Simonneau G et al., J Am 
Coll Cardiol. 2004 Jun 16;43:5S-12S). 
        
In addition, a functional classification (Table 2, Page 4) patterned after the New 
York Heart Association (NYHA) for heart disease was developed to allow 
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comparisons of patients with respect to the clinical severity of the disease 
process (8).  
 
Table 2: Functional Classification NYHA 
 
 
Class 
 
 
Description 
 
I 
 
 
 
II 
 
 
 
 
III 
 
 
 
 
IV 
 
Patients with pulmonary hypertension but without resulting 
limitation of physical activity. Ordinary physical activity does not 
cause undue dyspnea or fatigue, chest pain or near syncope. 
 
Patients with pulmonary hypertension resulting in slight limitation 
of physical activity. They are comfortable at rest. Ordinary 
physical activity causes undue dyspnea or fatigue, chest pain or 
near syncope. 
 
Patients with pulmonary hypertension resulting in marked 
limitation of physical activity. They are comfortable at rest. Less 
than ordinary physical activity causes undue dyspnea or fatigue, 
chest pain or near syncope. 
 
Patients with pulmonary hypertension with inability to carry out 
any physical activity without symptoms. These patients manifest 
signs of right heart failure. Dyspnea and/or fatigue may even be 
present at rest. Discomfort is increased by any physical activity. 
 
 
(Rich S. Primary pulmonary hypertension: executive summary. Evian, France: World Health 
Organization, 1998).  
 
1.2 Histopathology 
Histopathologically, the pulmonary arteries in PAH patients showed intimal 
thickening, medial hypertrophy, adventitial thickening, obliteration of small 
arteries, and occasionally, vasculitis in the walls of the pulmonary veins (Figure 
1). A fascinating focal vascular structure, the plexiform lesion, is also found in 
many cases of PAH (9-11). 
Plexiform lesion: is a focal proliferation of endothelial channel lined by 
myofibroblasts, smooth muscle cells and connective tissue matrix. They 
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represent a mass of disorganized vessels that arise from pre-existing pulmonary 
arteries (Figure 1A, B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Histology of PAH. (A), Plexiform lesion (magnification 10X). Note plexiform lesion 
occurs distal to vascular obstruction, suggesting a role for angiogenesis in its origin. (B), 
Magnification of plexiform lesion seen in A magnification 25X). (C), Intimal fibrosis of small 
pulmonary artery causing vascular obstruction (magnification 25X). (D), Medial hypertrophy 
(magnification 25X). (Archer S et al., Circulation. 2000)   
 
Intimal fibrosis: is a thickening and fibrosis of intimal layer due to migration and 
proliferation of smooth muscle cells, fibroblast and myofibroblast into the intima. 
This may arise in concentric luminar, eccentric or concentric non luminar fashion. 
In addition, a hallmark of severe pulmonary hypertension the neointima is the 
formation of a layer of myofibroblasts and extracellular matrix between the 
endothelium and the internal elastic lamina, termed the neointima (Figure 1C).  
Media hypertrophy: is an increase in the cross sectional area of the media of 
pre and intra acinar pulmonary arteries. This originates due to both hypertrophy 
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and hyperplasia of smooth muscle fibres as well as increase in connective tissue 
matrix and elastic fibres in the media of muscular arteries (Figure 1D).  
Adventitial thickening: is a thickening of adventitia due to increased fibroblast 
cellularity and extracellular matrix (ECM) deposition. This is highly prominent in 
the small, muscular pulmonary arteries and occurs in most cases of PAH. 
Nevertheless, it is extremely difficult to evaluate.  
All the above changes are seen typically in clinical classification IPAH; FPAH and 
APAH. Histopathological changes in various forms of PAH are qualitatively 
similar but with quantitative differences in the distribution and prevalence of 
pathological changes in the different components of the pulmonary vascular bed 
including arterioles, capillaries and veins.  
 
1.3 Pathophysiology/Pathological mechanisms 
The pathogenesis of IPAH is complex and multifactorial. Increased pulmonary 
vascular resistance in IPAH patients probably results from a combination of 
pulmonary vasoconstriction, vascular-wall remodeling and thrombosis. However, 
a growing body of evidence implicates the central role of endothelial dysfunction 
in the initiation and progression of IPAH. 
 
1.3.1 Endothelial dysfunction/Vasoconstriction 
One of the complex and multifactorial processes that contribute to the 
development of pulmonary hypertension involves endothelial cell dysfunction. 
Endothelial cells play an integral role in the maintenance of normal vascular 
structure and function. An injury and subsequent dysfunction of the endothelium 
causes altered production of endothelial mediators and growth factors that 
thereby facilitates vasoconstriction and pulmonary arterial smooth muscle cell 
(PASMC) hypertrophy, leading to pulmonary vascular remodeling and in situ 
thrombosis (Figure 2, Page 8) (12,13). 
The mechanisms responsible for endothelial activation are yet to be fully 
elucidated. However, a number of stimuli, including cytokines, viral infection 
(HIV), free radicals, shear stress from increased pulmonary blood flow, and 
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alveolar hypoxia, may potentially activate vascular endothelial cells to elicit basic 
alterations in their local production of vasoactive and vasoconstrictive mediators. 
The abnormal balance of these mediators in the pulmonary vasculature 
culminates in the development of endothelial cell proliferation and 
vasoconstriction (14,15). Though, it is yet unclear whether a disturbance in 
humoral mediators causes pulmonary hypertension or is a result of it. Of those 
local mediators, nitric oxide, prostacyclin, and endothelin-1 are among the best 
studied and most commonly implicated in the pathogenesis of IPAH.  
 
1.3.1.1 Nitric oxide 
Nitric oxide (NO)/Endothelium derived relaxing factor (EDRF) is a potent 
vasodilator and an inhibitor of platelet activation and vascular smooth-muscle cell 
proliferation (16,17). Nitric oxide (NO) is constitutively produced in the lung 
endothelium by endothelial nitric oxide synthase (eNOS). Nonetheless, the 
expression of eNOS can be modulated by diverse stimuli such as shear stress 
and increased pulmonary blood flow (18). 
Interestingly, patients with IPAH have low levels of NO in their exhaled breath. In 
fact, the severity of pulmonary hypertension correlates inversely with NO levels 
estimated by measurement of NO reaction products in bronchoalveolar lavage 
fluid (19). Furthermore, decreased levels of the eNOS have been observed in the 
pulmonary vascular tissue of patients with pulmonary hypertension, particularly 
those with IPAH (20,21). Though, controversial reports exist in concern to eNOS 
expression in IPAH patients, which were discussed in detail in later part of the 
thesis. 
 
1.3.1.2 Endothelin-1 
Endothelin-1 (ET-1) produced by human endothelial cells, is the most potent 
vasoconstrictor and mitogen, with the ability to induce cell proliferation in a 
number of cell types, including vascular smooth muscle cells. The peptide exerts 
its biologic effects via interacting with two G-protein-coupled receptors, ETA and 
ETB (22). In patients with IPAH, several derangements in ET-1 expression and 
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activity have been demonstrated. Patients with IPAH have been shown to have 
higher serum levels of ET-1 and higher arterial-to-venous ratios of ET-1 than do 
healthy controls. Endothelin levels have also been shown to correlate with 
pulmonary hemodynamics (23). In addition, lung specimens from patients with 
IPAH when compared to healthy donors, exhibit increased ET-1 staining of the 
muscular pulmonary arteries (24). 
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Figure 2: Pathogenesis of pulmonary arterial hypertension (PAH). Schematic outline of 
abnormalities seen in PAH that may contribute to its cause or progression. An injury and 
subsequent dysfunction of the endothelium by a variety of stimuli causes altered production of 
endothelial mediators and growth factors that thereby facilitates vasoconstriction and pulmonary 
arterial cell types (endothelial cells (EC), smooth muscle cells (SMC) and fibroblasts (FB)) 
proliferation and migration, leading to pulmonary vascular remodeling and in situ thrombosis. The 
reduction of cross-sectional area of the pulmonary microvasculature contributes to the increased 
pulmonary vascular resistance observed in this disease (Author's Slide). 
 
1.3.1.3 Prostacyclin 
The endothelium also produces prostacyclin (PGI2) by cyclooxygenase 
metabolism of arachidonic acid. It possesses strong vasodilatory, anti-
aggregatory, anti-inflammatory, and anti-proliferative properties (25). Prostacyclin 
synthesis is disturbed in endothelial cells of IPAH patients. Analysis of urinary 
metabolites of prostacyclin showed a decreased excretion of 6-ketoprostaglandin 
F1, a stable metabolite of prostacyclin in patients with IPAH (26). In addition, a 
decrease in prostacyclin synthase expression has been noted in pulmonary 
arteries of patients with severe IPAH, portopulmonary hypertension and HIV-
associated PAH, further underscoring the role of endothelial dysfunction in the 
pathobiology of PAH (27). 
 
1.3.2 Remodeling 
In addition to pulmonary vasoconstriction that results from dysregulation of the 
local endothelial mediators as discussed above, pulmonary vascular remodeling 
seems to play a major role in the increased vascular resistance seen in IPAH 
(13). Pulmonary vascular remodeling is characterized by thickening of all three 
layers of the blood vessel wall, the adventitia, the media and the intima (28). The 
thickening is due to hypertrophy (cell growth) and/or hyperplasia (proliferation) of 
the predominant cell type within each of the layers and increased deposition of 
extracellular matrix components (e.g., collagen, elastin, and fibronectin) (29-32). 
These cellular changes usually results from the anti-mitogenic and mitogenic 
substances (NO, PGI2, and Endothelin) that are deranged by endothelial injury. 
In addition, other stimuli that derives from depolarized smooth muscle cells 
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(voltage-gated potassium channels (Kv)) and locally activated platelets 
(thromboxane A2 and serotonin) also plays a major role in the vascular cell 
proliferation. 
 
1.3.2.1 Serotonin  
Serotonin (5-hydroxytryptamine) is a vasoconstrictor that promotes smooth-
muscle cell hypertrophy and hyperplasia. A role of 5-HT has been suggested in 
IPAH. Plasma serotonin levels are increased in IPAH patients compared with 
control subjects, and IPAH platelets have decreased serotonin concentrations 
(33). These increased levels were shown to be associated with mutations in the 
serotonin transporter (5-HTT), the 5-hydroxytryptamine 2b receptor (5-HT2B), or 
both that have been described in platelets and lung tissue from patients with 
IPAH (34). Most interestingly, various studies suggest that appetite suppressant, 
aminorex fumarate induced risk of IPAH is mainly mediated via its interaction 
with serotonin transporter, 5-HTT (6). 
 
1.3.2.2 Potassium channels 
Potassium channels are the transmembrane-spanning proteins that have a 
greater selectivity for K+ ions. There are three major classes K+ channels 
channels: Kv channels (including Ca2+-sensitive channels, KCa), the inward 
rectifier channels (Kir), and a family with a tandem, 2-pore motif (TASK). Among 
these, Kv channels have a voltage sensor and both respond to and contribute to 
determining membrane potential in PASMCs (35). However, patients with IPAH 
have low expression Kv1.5 channel that lead to membrane depolarization of 
PASMCs and to an increase in intracellular calcium resulting in both 
vasoconstriction and proliferation (36,37).  
 
1.3.2.3 Thromboxane  
Thromboxane, like prostacyclin, is an arachidonic acid metabolite and produced 
by endothelial cells and platelets. It is a potent vasoconstrictor, a smooth muscle 
mitogen, and an inducer of platelet aggregation (25). An increased production of 
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thromboxane A2 metabolites is seen in IPAH (26). Furthermore, thromboxane-
receptor density is increased in the right ventricle of patients with IPAH (38). 
 
1.3.3 In situ thrombosis 
The third major characteristic pathophysiologic abnormality in pulmonary 
hypertension is in situ thrombosis. It is believed to be initiated by abnormalities in 
the clotting cascade, the endothelial cells, or the platelets and thereby promoting 
the release of procoagulation mediators (39). Indeed, intravascular coagulation 
seems to be a continuous process in IPAH patients, characterized by increased 
blood thrombin activity and decreased thrombomodulin expression (40,41). In 
addition, PGI2 and NO, both inhibitors of platelet aggregation, are decreased at 
the level of the injured endothelial cell, as discussed above.  
Furthermore, circulating platelets in patients with IPAH seem to be in a 
continuous state of activation and contribute to the prothrombotic milieu by 
aggregating at the level of the injured endothelial cells (42). In most cases, 
however, it remains unclear whether thrombosis and platelet dysfunction are 
causes or consequences of the disease. 
 
1.4 Diagnosis and evaluation 
1.4.1 Clinical presentation 
The onset of IPAH symptoms is usually insidious with several years elapsing 
before the diagnosis is actually made. Furthermore, pulmonary hypertension 
often presents with nonspecific symptoms. The most common initial clinical 
manifestation of IPAH is dyspnea, which is most apparent during effort or 
exercise (43). General fatigue and chest pain are common complaints as well. 
Other signs that are presented as the disease progresses include cyanosis, 
raised jugular venous pressure, right-ventricular heave, loud pulmonary 
component of the second heart sound, murmurs of tricuspid regurgitation, 
hepatomegaly, ascites and peripheral edema (44,45). An adaptation of the NYHA 
classification of functional capacity has proven useful in qualitatively assessing 
disease progression (Table 2, Page 4). 
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1.4.2 Diagnostic evaluation 
A high index of suspicion, a meticulous history and a careful physical 
examination are paramount to the diagnosis of IPAH (45). Patients with above 
mentioned signs and symptoms were initially investigated with 
electrocardiogram, chest radiograph, and respiratory function tests. Once they 
were suspected of pulmonary hypertension, an extensive evaluation was 
performed to determine the etiology, severity and the responsiveness to 
vasodilator challenge. It includes echocardiography, serologic evaluations, 
ventilation-perfusion (V/Q) scanning, pulmonary function testing and an 
assessment of functional capacity (6 min walk test). The final step in this 
evaluation is right heart catheterization for the assessment of 
vasoresponsiveness (46). 
 
1.5 Treatment  
No cure for IPAH currently exists. However, medical therapies currently available 
can improve the functional status and quality of life of the patients. Treatment for 
IPAH patients begins with conventional therapies for the treatment include 
anticoagulants, inotropic agents, diuretics, and supplemental oxygen (47).  
The anticoagulant agent warfarin is recommended for use by all patients with 
IPAH in order to prevent further formation of thrombotic lesions in the pulmonary 
arterioles. Retrospective and prospective studies have demonstrated that 
warfarin treatment is associated with increased survival. Diuretics are 
recommended if edema is present and adapted to prevent an excessive 
decrease in right ventricular preloads in the presence of tricuspid regurgitation. 
Further, as hypoxia is a potent stimulus to vasoconstriction, oxygen requirements 
should be assessed at rest and during exercise, and oxygen should be 
supplemented to achieve a saturation of >90% at all times (47,48). 
Apart from the above, vasodilator therapy is considered to be the mainstay of 
treatment in patients with IPAH. Such therapy is used in an attempt to reduce 
pulmonary artery pressure and, thus, right-ventricular afterload. Before 
vasodilator therapy is initiated for IPAH, patients should be identified as 
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“responders” or “nonresponders” by measuring the change in pulmonary artery 
pressure and pulmonary vascular resistance in response to short-acting 
vasodilators such as inhaled nitric oxide, intravenous prostacyclin, or adenosine. 
Patients with a positive response (>20% reduction in mean pulmonary arterial 
pressure (mPAP) or pulmonary vascular resistance (mPVR)) are more likely to 
benefit from long term vasodilator therapy with calcium channel blockers (CCB) 
(49). During acute vasodilator testing, these patients showed significantly lower 
levels of both mPAP and mPVR, which reached near-normal values. Patients 
with a vasodilator response of this magnitude who are treated with a CCB have a 
reported survival of up to 94% at five years (compared with 38% in those who 
failed to respond and were not treated with a CCB). Nevertheless only a small 
subgroup of patients with PAH benefits from CCB therapy (<25%) (50).  
As the medical therapies with pure vasodilators have provided little or no 
beneficial effects on survival in the vast majority of patients, the focus of the 
treatment in recent years has changed from vasodilators to anti-proliferative 
agents. Goals of specific IPAH therapy should include reduction of pulmonary 
pressure and pulmonary vascular resistance, inhibition or reversal of pulmonary 
vascular remodelling and improvement of right ventricular function. 
 
1.5.1 Prostacyclin analogues 
These agents act through an increase in cAMP, thereby mediating vasodilation 
and inhibition of platelet aggregation and PASMCs proliferation. Continuous 
intravenous infusion of epoprostenol (PGI2 analogue) for 3 months, in a 
prospective, randomized, controlled trial in 81 patients with class III or IV IPAH 
demonstrated improved survival and exercise tolerance, increased cardiac 
output, and decreased pulmonary vascular resistance (51). Moreover, a 
significant improvement occurred in patients who do not respond acutely to 
pulmonary vasodilatation, indicating that long-term treatment may be influencing 
cellular proliferation, a crucial mechanism in pulmonary vascular remodeling (52). 
However, due to the lack of pulmonary selectivity, intravenous epoprostenol may 
induce hypotension and worsening of the ventilation-perfusion mismatch. In 
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addition, use of epoprostenol is complicated with short half-life, cost and 
complicated modes of delivery.  
Nonetheless, the beneficial effects of continuous PGI2 therapy have led to trials 
using more stable analogues and alternative routes of administration. These 
include iloprost, available for intravenous, oral and inhalation use; UT-15, which 
is administered subcutaneously; beraprost, an orally active analogue. Inhaled 
iloprost, a stable prostacyclin analogue holds great promise in the PAH 
treatment. A randomized double-blind placebo-controlled multicentre trial of three 
months duration conducted in Europe in 203 patients with severe PAH 
demonstrated improved exercise capacity, symptoms, hemodynamic and quality 
of life in actively treated patients compared to placebo (53). 
 
1.5.2 Inhaled nitric oxide 
Since pulmonary arterial hypertension is associated with a defect in the 
production of potent and pulmonary specific vasodilator - nitric oxide, 
supplementation with inhaled nitric oxide (iNO) has been proposed as a potential 
therapy (54). Short-term inhalation of nitric oxide has substantial pulmonary 
specific vasodilator effects and proved beneficial in the treatment of IPAH (55). 
However, this treatment modality suffers from two potential complications. First, 
iNO causes increase in the pulmonary artery wedge pressure subsequent to 
pulmonary edema formation. Second, sudden termination of iNO occasionally 
causes a potentially life threatening hypertensive rebound effect. In addition, long 
term iNO therapy in large number of IPAH patients is limited by its short half life 
and cost (55,56). 
 
1.5.3 Endothelin antagonists 
As described above, endothelin plays a significant pathogenetic role in the 
development and progression of IPAH. Bosentan, an orally active dual endothelin 
receptor ETA /ETB antagonist, has been evaluated in a large randomized 16-
week trial with NYHA class III and IV IPAH and PAH related connective tissue 
disease. Bosentan improved pulmonary hemodynamics, exercise capacity, 
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functional status, and the clinical outcome (57,58). However, severe side effects 
such as abnormal hepatic function and anemia developed in a significant 
percentage of patients taking this drug. 
 
1.5.4 Phosphodiesterase inhibitors  
Cyclic nucleotide phosphodiesterases (PDEs) comprise a large and complex 
group of structurally related enzymes, which catalyze the hydrolysis of cAMP and 
cGMP, and thereby regulate intracellular concentrations of these important 
"second messengers". In this manner, PDEs can affect various biological 
processes including the effects mediated by nitric oxide and prostanoids. Till 
date, eleven different mammalian PDE gene families have been identified 
(59,60). Of these, PDE5 is shown to be largely responsible for cGMP metabolism 
in the lung (61). The development of potent and selective PDE5 inhibitors, such 
as sildenafil, E4021, and E4010, has provided an opportunity to examine the 
effects of PDE5 inhibition as a treatment for PAH.  
Sildenafil, when used for the treatment, has been shown to have acute 
hemodynamic effects in IPAH (61,62). Its clinical use in patients with IPAH in 
several, nonrandomized trials has been associated with improvements in function 
and hemodynamics (63). Thereby, suggesting the therapeutic efficiency of PDE5 
inhibitors in IPAH and drives towards exploiting other PDE subtypes and their 
inhibitors in this disease.  
Though not described in detail, other potential therapies include vasoactive 
intestinal peptides and selective serotonin reuptake inhibitors. 
 
1.6 Nitric Oxide 
NO is a gaseous free radical with only a few seconds of biological half-life, and 
has been identified as critical player in a remarkable array of essential biological 
processes, ranging from neurotransmission, the control of vascular tone, 
apoptosis to inflammation (16,64). 
A glance back in history of NO, early studies by Furchgott and Zawadski 
demonstrated that endothelial cells are able to release a labile factor upon 
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acetylcholine stimulation, named as endothelium derived relaxing factor (EDRF) 
that diffuses to the adjacent muscle layer and causes vasorelaxation (65). 
Finally, in 1987, Ignarro and colleagues pharmacologically and chemically proved 
EDRF to be NO (66). This discovery and subsequent findings related to its 
biological functions such as platelet aggregation, vasodilation and 
neurotransmission were honored by Nobel Prize in 1998.  
 
1.6.1 Nitric oxide synthase 
NO is synthesized from amino acid L-arginine by a family of enzymes termed 
nitric oxide synthases (NOS) (67). Nitric oxide synthases are dimeric heme 
containing enzymes composed of oxygenase and reductase domains which 
possess binding sites for flavine dinucleotide (FAD), flavine mononucleotide 
(FMN), calmodulin (CaM) and tetrahydrobiopterin (BH4). In its active form, NOS 
forms a tetramer where two NOS monomers associate with two calmodulins and 
catalyzes five-electron oxidation of the terminal guanidino nitrogen atoms of L-
arginine to generate L-citrulline and NO (Figure 3, Page 17) (68). 
To date, three distinct isoforms of NOS enzymes have been identified, they are 
neuronal (nNOS or NOS1), inducible (iNOS or NOS2) and endothelial (eNOS or 
NOS3) NOS, the genes for which are located on chromosomes 12, 17 and 7 
respectively (17). NOS 1, 2 and 3 were originally purified from neurons, vascular 
endothelium and cytokine-induced macrophages although the three isoforms are 
now known to be distributed across a wide spectrum of cell types and tissues. 
Furthermore, a particular type of cell can express more than one isoform of NOS 
(69). 
Despite distinctions, due to high degree of sequence homology at c-terminal 
reductase domain, all NOS isoforms share important biochemical features mainly 
in concern to catalysis. All are NADPH and calmodulin-dependent and contain 
consensus binding sites for FAD and FMN, BH4, and a heme complex and 
mediates a five-electron oxidation of L-arginine to form NO and L-citrulline (68). 
Notably, for all three NOS isoforms, NO synthesis depends upon the enzyme's 
binding of the ubiquitous calcium regulatory protein calmodulin. For eNOS and 
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nNOS, increases in resting intracellular Ca2+ concentrations [Ca2+i] are required 
for their binding to calmodulin and, consequently, for their becoming fully 
activated. In contrast, iNOS appears able to bind calmodulin with extremely high 
affinity even at the low [Ca2+i] characteristic of resting cells. Thus, the intracellular 
activity of the eNOS and nNOS may be closely modulated by transient changes 
in [Ca2+i], and signaling molecules such as bradykinin, acetylcholine and 
glutamate that increases intracellular Ca2+ concentration through receptor 
associated mechanisms (17,18). On the contrary, iNOS activity is no longer 
temporally regulated by intracellular calcium transients. Its expression and 
activity can be induced by various cytokines and produces huge amounts of NO 
for long periods of time (70). 
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Figure 3: Nitric Oxide (NO) synthesis. NO is synthesized from the amino acid L-arginine by 
endothelial nitric oxide synthase (eNOS) in endothelial cells. Under basal conditions, eNOS is 
tethered to caveolin-1 (Cav-1) and inactive. However, with agonist (Bradykinin or fluid shear 
stress) induced increases in intracellular Ca2+, calmodulin (CaM) binds to eNOS and displaces 
Cav-1 in a mechanism facilitated by cooperative binding of hsp-90, leading to activation of eNOS 
activity. In addition, kinases like Akt and PKA also facilitates CaM interaction with eNOS. The 
activated eNOS then translocates to the cytoplasm where it catalyzes NO generation from the 
amino acid L-arginine that was transported inside the cell via. a family of transporters called 
cationic amino acid transporter (CAT-2B). Tetrahydrobiopterin (BH4) is an important cofactor 
needed for NO generation (Author's Slide).  
 
As discussed above, NO is a potent vasodilator known and plays an important 
role to maintain the stability of systemic and pulmonary hemodynamics. It causes 
relaxation by diffusing across the endothelial cell and stimulating soluble 
guanylate cyclase on the vascular smooth muscle cell. This converts GTP into 
cGMP. Relaxation results from an accumulation of cGMP, which then modifies 
several intracellular processes, lowers intracellular calcium and inhibits the 
contractile apparatus within the vascular smooth muscle cell (71). In addition, NO 
can also directly activate calcium-dependent potassium channels (72) leading to 
endothelium-dependent hyperpolarization of vascular smooth muscle cells, 
resulting in vasodilation.  
The effects mediated NO are versatile and multifactorial. Beyond vasodilation, it 
also regulates leukocyte adhesion to the endothelium, inhibits vascular smooth 
muscle cell proliferation, apoptosis, platelet aggregation, and angiogenesis 
(Figure 4, Page 19). These intracellular processes are mediated not only by 
cGMP-dependent but also in a guanylate cyclase and cGMP - independent 
manner. cGMP independent biological functions involving high levels of NO, 
where NO reacts with superoxide anion (O2-) to yield peroxynitrite anion  (ONOO-
). Peroxynitrite by lipid peroxidation, direct deamination of DNA and inactivation 
of proteins mediates cytotoxic effects and tissue injury the effects that were 
mainly observed in iNOS induced inflammation. These controversial responses, 
cytoprotective and cytotoxic, can only be explained by direct and indirect 
interactions of nitric oxide (73).  
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Figure 4: Pleotropic effects of Nitric oxide (NO). NO is an important molecular mediator of 
numerous physiologic processes in virtually every organ. In the vasculature, endothelium derived 
NO plays a crucial role in the regulation of vascular tone, inflammation, growth and the pro-
thrombotic and anti-thrombotic properties (Author's Slide). 
 
1.6.2 Regulation of NO 
Due to short biological half-life and rapid diffusion rates, the cellular 
concentrations of NO are mainly dependent on rates of synthesis by the enzyme 
nitric oxide synthase (NOS). Therefore, cellular concentrations of NO depend on 
(i) NOS expression, (ii) NOS activity, (iii) substrate availability, (iv) NO half life, 
and (v) sensitivity to NO.  
Although eNOS is constitutively expressed in vascular endothelial cells, both in 
vivo and vitro studies have demonstrated that basal expression and stability of 
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eNOS mRNA can be influenced by several stimuli. Shear stress, estrogen, 
lysophosphatidylcholine, and oxidized low density lipoprotein have been found to 
upregulate eNOS expression. On the other hand, tumor necrosis factor-α (TNF-
 α), erythropoietin, and high concentrations of oxidized LDL downregulates eNOS 
expression (74,75). Most interestingly, as a negative-feedback regulatory 
mechanism eNOS expression is modulated by NO itself via a cGMP-mediated 
process (76). 
NO production in the endothelial cells can also be influenced by posttranslational 
modifications and subcellular targeting of eNOS. These post-translational 
modifications include phosphorylation, N-myristoylation and thiopalmitoylation. 
Studies from many research groups have indicated that the localization of eNOS 
within the cell, mainly at caveolae also determines its activity. In caveolae, 
caveolin-1 inhibits eNOS activity is by interfering with the calmodulin binding site. 
Factors like Ca2+i increase, shear stress and certain post-translational 
modifications were shown to displace caveolin-1 and subsequently eNOS 
activation. Besides these, changes in substrate and cofactor availability, protein–
protein interactions and phosphorylation state have gained importance as 
significant regulators of NOS activity (77). 
The amino acid L-arginine is the only physiological substrate for NOS; hence 
regulation of its availability could be a major determinant in NO production. 
Interestingly, intracellular levels of L-arginine far exceed the Km of the NOS 
enzyme, so its availability is unlikely ever to be the rate-limiting step in the 
formation of NO by the endothelium in normal physiological conditions. However, 
a number of in vivo and in vitro experiments have shown that L-arginine 
availability can be rate-limiting for the generation of NO; especially in endothelial 
dysfunction associated pathophysiological conditions. This availability of L-
arginine is not only influenced by its synthesis and degradation but also by its 
transcellular transport into the cell (77,78). A high-affinity carrier resembling the 
cationic amino acid transport (CAT) system y+ is responsible for the transcellular 
transport of L-arginine and its analogues. The transporter activity is mediated by 
the CAT family that is composed of four isoforms, CAT-1, CAT-2A, CAT-2B, and 
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CAT-3. The recent finding that y+ transporter co-locates with caveolin-bound 
eNOS suggest that activity of this transporter may be important to determine the 
local concentrations of L-arginine and their analogues (79). Various exogenous 
stimuli such as lipopolysaccharide (LPS), interleukin-1ß (IL-1ß), TNF-α, insulin, 
angiotensin II and  bradykinin have been found to stimulate the L-arginine 
transport into endothelial cells by the y+ system, which may increase NO 
production (80). Finally, an increasing number of reports in the literature indicate 
that endogenously produced inhibitors of NOS majorly regulate NO generation 
and may be responsible in numerous endothelial dysfunction associated disease 
states.  
 
1.6.2.1 Endogenous NOS inhibitors 
The guanidino-methylated L-arginine analogues NG, monomethyl-L-arginine (L-
NMMA), NG,NG-asymmetric dimethylarginines (ADMA); NG,NG-symmetric 
dimethylarginines (SDMA) have been shown to endogenously modulate L-
arginine handling and / or NO synthesis in biological systems (Figure 5).  
 
 
 
 
 
 
 
 
 
Figure 5: Chemical structures of methylarginines. (Masuda H, Nippon Yakurigaku Zasshi. 
2002) 
The biological significance of guanidino-methylated L-arginine analogues, mainly 
L-NMMA was first identified in 1986 as a compound that inhibits cytotoxic effects 
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of activated macrophages and prevents the release of nitrite and nitrate derived 
from L-arginine within these cells (81). Afterwards, L-NMMA became the 
standard nitric oxide synthase inhibitor used to evaluate the role of the L-arginine 
- nitric oxide pathway.   
Methylarginines are endogenously derived from the proteolysis of methylated 
arginine residues on wide range of highly specialized nuclear proteins that are 
involved in RNA processing and transcriptional control (82). The methylation is 
carried out by a group of enzymes referred to as protein-arginine methyl 
transferases (PRMT) (83). Subsequent proteolysis of proteins containing 
methylarginine groups leads to the release of free methylarginine into the 
cytoplasm.  However, the release of specific methylarginines depends on the 
subtypes of PRMT (PRMT I and PRMT II). PRMT type I catalyses the production 
of L-NMMA and ADMA in non-myelin basic protein substrates whereas PRMT 
type II catalyzes L-NMMA and SDMA in myelin basic protein substrates.  
Plasma L-NMMA, ADMA and SDMA enter the cell through the y+ cationic amino 
acid transporter and most interestingly they compete with each other as well as 
with L-arginine for transport (80). In addition, among these L-NMMA and ADMA 
effectively inhibits NOS but not SDMA. In cases of L-arginine limitation, they can 
even influence eNOS to generate even free oxygen radicals (84). However, 
ADMA seems to be more important as it is predominantly present (10 fold 
greater) than L-NMMA in plasma.  
Once methyl arginines are released from methylated proteins by proteolysis, the 
two principal factors controlling levels are renal clearance and metabolism 
(85,86). SDMA is largely cleared by renal excretion. By contrast, the vast majority 
of ADMA and L-NMMA generated within the body is metabolized by the enzyme 
dimethylarginine dimethylaminohydrolase (DDAH) (Figure 6, Page 23). 
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Figure 6: Schematic overview of the biochemical pathways related to methylarginines. 
Methylation of arginine residues within proteins or polypeptides occurs through N-
methyltransferases (PRMTs), which utilize S-adenosylmethionine as a methyl group donor. After 
proteolytic breakdown of proteins, free ADMA, SDMA and L-NMMA are released into the 
cytoplasm. ADMA and L-NMMA acts as inhibitors of NOS by competing with the substrate of this 
enzyme, L-arginine, and causes endothelial dysfunction that was associated with various 
vascular diseases. SDMA can’t inhibit NOS but it can efficiently compete with substrate L-arginine 
for its intracellular transport. ADMA is eliminated from the body via metabolism by the enzyme 
dimethylarginine dimethylaminohydrolase (DDAH) to citrulline and dimethylamine (Boger RH, 
Cardiovasc Res. 2003). 
 
1.6.2.2 Dimethylarginine dimethylaminohydrolase (DDAH) 
Identified and purified from rat kidney in 1987 by Ogawa and co-workers DDAH 
demonstrated specific hydrolysis of ADMA and L-NMMA to L-citrulline and either 
mono- or dimethylamine (86). Several studies suggest that DDAH is the key 
elimination route for ADMA as 83% of ADMA that was generated each day in 
humans is metabolized by DDAH and remaining small amount via renal system. 
Further, inhibition of DDAH activity with specific inhibitor, S-2-amino-4(3-
methylguanidino) butanoic acid (4124W) on isolated vascular segments caused a 
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gradual vasoconstriction by elevating ADMA, evidenced for the first time the 
critical role of DDAH on ADMA levels and subsequent NO synthesis (87). This 
notion has been strengthened by recent observations made from a transgenic 
DDAH mouse model (88). The transgenic animals showed an increased DDAH 
activity and reduced ADMA levels. The reduction in plasma ADMA is associated 
with a significant increase in NOS activity and reduced systolic blood pressure, 
systemic vascular resistance, and cardiac stroke volume. 
To date, two isoforms of DDAH have been described, DDAH1 and 2 located on 
chromosome 1p22 and 6p21.3, respectively (89). The overall amino acid 
sequence similarity between both isoforms is approximately 62% and is highly 
conserved among species. Isoforms, DDAH1 and 2 show different specific tissue 
distributions, DDAH1 is typically found in tissues expressing nNOS, whereas 
DDAH2 predominates in tissues containing the endothelial isoform of NOS 
(eNOS), supporting the hypothesis that intracellular ADMA concentration is 
actively regulated by DDAH in NO-generating cells. 
Moreover, crystallographic analysis of DDAH have demonstrated that the active 
site of DDAH contains a free cysteine residue and one tightly bound non-catalytic 
zinc ion, which through reversible binding to the active site regulates the 
enzymatic activity (90), thus making it exquisitely sensitive to oxidative stress.  
Human endothelial cells synthesize methylarginines and ADMA is produced in 
quantities that may affect NO synthesis. Chronic exposure of cultured endothelial 
cells with ADMA (2µM) has demonstrated intriguing changes in endothelial 
behavior (91). Yet under physiological conditions the production of ADMA and its 
effects are balanced by DDAH. 
Intriguingly, plasma levels of ADMA were elevated and found to associate with 
endothelial vasodilator dysfunction in patients with coronary and peripheral 
arterial disease, and those with risk factors such as hypercholesterolemia, 
hyperhomocysteinemia, chronic renal failure and chronic heart failure (92-95). 
Specifically, each of these risk factors for cardiovascular disease is associated 
with endothelial oxidative stress and inactivation of DDAH (96,97). The impaired 
DDAH activity thereby allows ADMA to accumulate and to block NO synthesis. 
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Impaired DDAH activity in these disease conditions may be modulated by 
inflammatory cytokines, oxidized lipoproteins, glucose and homocysteine which 
are increased in endothelial oxidative stress. 
 
1.6.3 NO and pulmonary hypertension 
As described above, patients with IPAH have decreased levels of NO in their 
lungs, which may contribute to the development of pulmonary hypertension. 
Recently, patients with IPAH also illustrated reduced intrabronchial NO and NO 
biochemical reaction products compared with healthy individuals (19). 
Interestingly, the low levels of NO products correlated directly with the severity of 
disease. Even in experimental conditions, exposure to hypoxia impairs 
endothelium- dependent relaxation of isolated pulmonary vascular rings and the 
release of NO from cultured pulmonary endothelial cells (98). Thereby indicating 
the important role of NO axis in the regulation of vascular tone and remodeling of 
the hypertensive pulmonary circulation. The mechanisms of this impairment are 
undoubtedly multifactorial and may vary from patient to patient.  
On the other hand, eNOS expression levels in IPAH patients remains 
controversial.  Giaid and Saleh reported decreased eNOS expression (99) 
whereas Xue and Johns reported increased (100) and Tuder et al. unaltered 
eNOS immunostaining (27). While, eNOS expression is increased in the 
endothelium of the resistance pulmonary arteries in chronic hypoxia, 
Monocrotaline and the fawn hooded rats (101).  
Thus, decreased levels of NO in the face of normal or increased NOS expression 
can be explained only by impaired NOS activity. Activity of arginase, an enzyme 
that metabolizes L-arginine was higher in PAH serum than in controls, 
suggesting that substrate availability affects NOS activity in the pathophysiology 
of PAH (102). If so, supplementary L-arginine could theoretically reverse this 
abnormality. Conversely, L-arginine infusion did not show any long term 
beneficial effects in these patients (103). 
In experimental induced PAH, abnormal coupling with caveolin and HSP 90 were 
also shown to reduce NOS activation (104). Nevertheless, none of these entities 
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have shown to majorly influence the NO axis in pulmonary arterial hypertension. 
Despite the impact of endogenous NO-synthase inhibitors such as 
dimethylarginines (ADMA and SDMA) have come into the focus of attention for 
various endothelial dysfunction associated cardiovascular disorders. As current 
evidence strongly suggests a central role for endothelial dysfunction in the 
initiation and progression of IPAH, the plausible role of dimethylarginines is 
speculated in this disease. Hence forth, the present study was undertaken to 
investigate the potential role of dimethylarginines in the course of chronic 
pulmonary hypertension. 
 
Aims 
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2. Aims of the study 
 
Idiopathic pulmonary arterial hypertension (IPAH) is a progressive and life- 
limiting disorder which is associated with impaired bioactivity and/or synthesis of 
endogenous nitric oxide (NO). The mechanisms resulting in this impairment are 
multifactorial. Recently, the impact of endogenous NO-synthase inhibitors such 
as dimethylarginines (ADMA and SDMA) has come into the focus of attention in 
the pathogenesis and progression of various cardiovascular diseases associated 
with endothelial dysfunction. However, the potential role of dimethylarginines 
(ADMA and SDMA) in patients with IPAH has not yet been explored. 
The aim of the present study was to evaluate dimethylarginines levels in IPAH 
patients and monocrotaline induced pulmonary hypertensive (MCT-PAH) rats. 
This was accompanied by assessing the precise mechanisms responsible for the 
altered dimethylarginines such as protein arginine methylation and/or alterations 
of the metabolizing enzyme DDAH in the course of chronic pulmonary 
hypertension were also investigated.  This series of studies include the following 
aspects: 
 
1. To evaluate plasma levels of L-arginine, ADMA and SDMA in IPAH patients 
and in MCT- PAH rats. 
 
2. To evaluate biosynthesis of dimethylarginines in lung tissues from patients 
suffering from IPAH as well as on tissue from MCT- PAH rats. 
 
3. To evaluate expression of DDAH isoforms in lung tissues from patients 
suffering from IPAH as well as on tissue from MCT-PAH rats. 
 
4.  To elucidate the molecular mechanisms responsible for DDAH alterations. 
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5. To test the therapeutic efficacy of selective phosphodiesterase inhibitors 
(PDEi) on the pulmonary hemodynamics and structural and molecular 
changes underlying MCT - PAH rats. 
 
6. To test the hypothesis that selective PDEi may be effective in NO axis 
modulation and reversal of endothelial dysfunction associated with MCT-PAH.  
 
7. To elucidate the effects of PDEi on dimethylarginines and subsequently on 
their biosynthesis and metabolism. 
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3. Materials and Methods 
 
3.1. Materials 
For RT-PCR analysis of human and rat tissue 
huDDAH1 (NM_012137) 
Forward   5’ GCAACTTTAGATGGCGGAGA 3´  
Reverse   5’ TGGAAAGGCCCACAAAAA 3´ 
 
huDDAH2 (NM_013974) 
Forward   5’ CTGTTGTGGCAGGCAGCAG 3´  
Reverse   5’ GTCAGGGAGGCATATGGGTG 3´ 
 
huGAPDH (NM_002046) 
Forward   5’ CGTCATGGGTGTGAACCATG 3´  
Reverse   5’ GCTAAGCAGTTTGTGGTGCAG 3´ 
 
rDDAH1 (NM_022297) 
Forward   5’ ATGGTGGGGACGTCCTATTC 3´  
Reverse   5’ GCACCTCGTTGATTTGTCCT 3´ 
 
rDDAH2 (NM_212532) 
Forward   5’ AGGGTCCAGAGAGGCGTAGG 3´  
Reverse   5’ GGCTGGAAGCAGTGAGGCT 3´ 
 
rGAPDH (NM_017008) 
Forward   5’ GTGATGGGTGTGAACCACGAG 3´  
Reverse   5’ CCACGATGCCAAAGTTGTCA 3´ 
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Antibodies 
Antibodies used in the experiments are all commercially available. They were 
used for both western blot and immunohistochemistry until specifically specified.  
Primary antibodies        
Anti-DDAH1 (polyclonal) rabbit  Orbigen Inc, San Diego, USA 
Anti-DDAH2 (polyclonal) goat    Calbiochem, BadSoden,   
       Germany 
Anti-GAPDH (monoclonal) mouse   Abcam,Cambridge, UK  
Anti-ADMA (polyclonal) rabbit Upstate, Hamburg, Germany 
Anti-SDMA (polyclonal) rabbit      Upstate, Hamburg, Germany 
Anti-alpha actin (monoclonal) mouse  Sigma,Steinheim,Germany 
anti-von Willebrand factor (polyclonal) rabbit Dako, Hamburg, Germany 
 
HRP-conjugated secondary antibodies 
Anti-mouse IgG rabbit    Sigma,Steinheim,Germany 
Anti-rabbit IgG goat     Abcam,Cambridge, UK 
Anti-goat IgG rabbit     Abcam,Cambridge, UK 
 
Fluorophore-conjugated secondary antibodies 
Anti-goat IgG rabbit Texas red conjugated DakoCytomation, Hamburg, 
Germany 
Anti-rabbit IgG goat FITC conjugated Molecular Probes, Karlsruhe, 
Germany 
 
Kits 
Gibco, Eggenstein, Germany 
DNeasy Tissue kit     Qiagen, Hilden, Germany 
Gel extraction kit     Qiagen, Hilden, Germany 
 
qPCR™ Mastermix  Euro-genetec, Seraing, Belgium  
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Dye Reagent Concentrate Bio-Rad, Muenchen, Germany 
ECL detection kit      Amersham,Freiburg, Germany  
Vectastain ABC kit      Vector, Burlingame, USA  
Vector VIP substrate kit    Vector, Burlingame, USA 
Vector DAB substrate kit    Vector, Burlingame, USA 
 
Instruments 
Cardiotherm 500-X Harvard Apparatus GmbH, 
March-Hugstetten, Germany 
ABI 7700 Sequence Detection System   Applied Biosystems, Darmstadt, 
Germany 
Electrophoresis apparatus    Biometra, Gottingen, Germany 
Small animal ventilator IITC Life science, Woodland Hills, 
USA 
Photodiode array detector, Waters Corp, Milford, USA 
cation-exchange extraction cartridges  Waters Corp, Milford, USA 
BioDoc Analyzer  Biometra, Gottingen, Germany 
Minigel-Twin Biometra, Gottingen, Germany 
Semi dry transfer unit Biometra, Gottingen, Germany 
Dot blot apparatus  Bio-Rad, Richmond, USA 
Automatic vacuum tissue processor Leica, Bensheim, Germany 
Leica QWin Image Processing System  Leica, Bensheim, Germany 
T3 Thermocycler     Biometra, Gottingen, Germany 
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Table 3: Buffer solutions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Buffer or solution Components
1x PBS 7.2 g/L NaCl, 1.48 g/L Na2HPO4, 0.43 g/L KH2PO4, pH 7.4
1x Running buffer 3 g Tris base, 14.4 g Glycine, 10mL 10% SDS made to 1 Lit with DDH2O
Transfer buffer 6 g Tris base, 3 g Glycine, 200 mL Methanol to 1 Lit with DDH2O
5x Laemmli buffer 1.8 mL DDH2O, 2.5 mL 0.5 M Tris-HCl (pH 6.8), 2.5 mL Glycerol, 2 mL 20%
SDS, 1mL ß-mercaptoethanol,  0.2 mL 1% (w/v) Bromophenol blue (in water) 
Blocking solution 5 g Skim milk powder in 100 mL 1x TBST 
1x TBST 2.24 g Tris base, 8.85 g  NaCl, 1.8 g EDTA, 1 mL Tween 20 made to 
1 Lit with DDH2O
1x Lysis buffer 50 µl 1M Tris (pH 7.6), 10 µl 1M CaCl2,100µl 1.5 M NaCl, 100µl 0.6 M NaN3, 
10µl 10% Triton X, protease inhibitor cocktail made to 1 mL with DDH2O 
Sodium phosphate
Buffer (pH 7.2) 
68.4 mL 1 M Na2HPO4, 31.6 mL 1 M NaH2PO4
5x TAE buffer 54 g Tris base, 11 mL Acetic acid, 20 mL of 0.5 M EDTA 
(pH 8.0) to1 Lit with DDH2O
12.5 mL 0.5 M Tris-HCl (pH 6.8), 0.7 mL ß-Mercaptoethanol, 20 mL
10% SDS
Stripping buffer 
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3.2 Methods 
3.2.1 Patient characteristics and measurements 
Eleven consecutive patients referred to our centre for diagnosis and treatment 
suffering from idiopathic pulmonary arterial hypertension (according to the 
classification of the Third World Symposium on Pulmonary Arterial Hypertension; 
(all NYHA class III or IV) gave written informed consent before inclusion into the 
study. Standard diagnostic procedures (imaging techniques, clinical chemistry, 
lung function testing, echocardiography, etc.) excluded other than the above 
mentioned causes for pulmonary hypertension. All patients were treated with 
chronic oral anticoagulation and diuretics before, but none received specific 
therapy for the pulmonary hypertension at timepoint of inclusion. Venous blood 
samples were drawn after a minimum resting period of two hours. Pulmonary and 
systemic hemodynamics were assessed by right heart catheterization following 
standard procedures of our Pulmonary Hypertension Centre. Exercise capacity 
was assessed by means of six minute walking test (according to the guidelines of 
the American Thoracic Society). 
Human lung tissue was obtained from 7 donors and 7 IPAH patients undergoing 
lung transplantation. Patient lung tissue was snap frozen directly after 
explantation for mRNA and protein extraction or directly transferred into 4% 
buffered paraformaldehyde, fixed for 24 h at 4°C and embedded in paraffin. 
Hemodynamic measurements in 5 of the 7 IPAH patients who underwent 
transplantation revealed a mean pulmonary artery pressure of 68.4±8.5 mmHg. 
Tissue donation was regulated by the national ethical committee and national 
law. All patients enrolled in this study gave written informed consent.  
 
3.2.2 Animal experiments 
Adult male Sprague Dawley rats (300-350g body weight) were obtained from 
Charles River Laboratories (Sulzfeld, Germany). The experiments were 
performed in accordance with the National Institutes of Health Guidelines on the 
Use of Laboratory Animals. Both the University Animal Care Committee and the 
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Federal Authorities for Animal Research of the Regierungspräsidium Giessen 
(Hessen, Germany) approved the study protocol. 
 
3.2.3 MCT treatment 
The alkaloid Monocrotaline (MCT) (Sigma) was dissolved in 0.5 N HCl, and the 
pH was adjusted to 7.4 with 0.5 N NaOH. The MCT (20mg/ml) solution was given 
as a single subcutaneous injection (60 mg/kg) to male Sprague-Dawley rats. 
Control rats received an equal volume of isotonic saline.  
 
3.2.4 Chronic dosing study 
For chronic intervention studies, rats were randomized to receive either placebo 
or tolafentrine by osmotic minipumps. Tolafentrine (chemical name : (-)-cis-8,9-
Dimethoxy-1,2,3,4,4a-10b-hexahydro-2-methyl-6-(4-p-toluenesulfonamido-
phenyl)-benzo[c][1,6]naphthyridine) was synthesized in the laboratories of 
ALTANA Pharma, Konstanz, Germany. Tolafentrine, the active drug, is a mixed 
selective PDE3/4 inhibitor with PDE3 inhibitory activity with an IC50 of 60 nmol/L 
and inhibiting activity of PDE4 with an IC50 of 100 nmol/L. The dose of 
tolafentrine (625 ng/kg per minute) was chosen according to preceding pilot 
experiments, addressing long-term tolerability of this agent under investigation. 
Treatment was started 2 weeks after injection of MCT, during development of 
pulmonary hypertension, for duration of 2 weeks.  
 
3.2.5 Surgical preparation and tissue preparation 
Two weeks after a single MCT injection, rats were subjected to inhalation of 
tolafentrine or sham nebulization in an unrestrained, whole body aerosol 
exposure system as described. For assessment of chronic effects of inhaled 
saline or tolafentrine (dose deposited in the lungs ~ 120 µg/kg day), 15 min 
nebulization maneuvers using a jet nebulizer with a constant flow rate of 6 l/min 
(Pari LC Star, Pari, Starnberg, Germany) were repeated twelve times per day for 
2 weeks (day 14 – 28).  
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At the end of the treatment protocol, the animals were anesthetized with 
intraperitoneal pentobarbital and tracheostomized. They were artificially 
ventilated with a small animal ventilator 10 ml per kg body weight (BW) and a 
frequency of 60 s-1. Inspiratory oxygen (FIO2) was set at 0.5, and a positive end-
expiratory pressure of 1.5 cm H2O was used throughout. Anesthesia was 
maintained by inhalation of isoflurane. The left carotid artery was cannulated for 
arterial pressure monitoring, and a right heart catheter (PE 50 tubing) was 
inserted through the right jugular vein for measurement of right ventricular 
systolic pressure (RVSP) with fluid-filled force transducers (zero referenced at 
the helium). Cardiac output (CO) was measured by thermodilution technique 
using Cardiotherm 500-X. Briefly, a thermistor (1.5F) was placed into the 
ascending thoracic aorta via the right carotid artery for measurement of 
transpulmonary thermodilution CO. A 0.15-mL bolus of room-temperature saline 
was injected into the right ventricle as the indicator. CO was averaged from three 
consecutive determinations and indexed to the weight of the animal to obtain 
cardiac index.  
Arterial and mixed venous samples were collected (150 µl) and analyzed for PO2, 
pH and PCO2. Hemoglobin and oxygen saturation were measured using an 
OSM2 Hemoximeter. After exsanguination, the lungs were flushed with isotonic 
saline at a constant pressure of 22 cm H2O via the pulmonary artery. The right 
lung was ligated at the hilus and shock frozen in liquid nitrogen, and stored at –
80 °C for molecular studies. The left lobe was perfused for 5 minutes with 
Zamboni’s fixative at a pressure of 22 cm H2O via the pulmonary artery. The 
tissue was fixed in Zamboni’s fixative for 12 hours at 4°C and then transferred 
into 0.1 M phosphate buffer. 
As an index of right ventricular hypertrophy, the ratio of the right ventricle weight 
to left ventricle plus septum weight (RV/LV+S) was calculated. 
 
3.2.6 RNA isolation 
Total RNA was isolated from exponentially growing cells and lung tissue 
homogenates using TRIzol® reagent. 100 mg of lung tissues were homogenized 
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in 1.0 ml TRIzol® reagent using polytron homogenizer and incubated for 10 min. 
Following 10 min incubation, 200 µl of chloroform was added to these samples. 
Samples were shaken vigorously by hand for 15 sec and incubated at 15-30°C 
for 2-3 min and centrifuged at 12,000 x g for 15 min at 4°C. The aqueous phase 
was removed after centrifugation and RNA was precipitated from the aqueous 
phase by adding 0.5 ml of isopropanol per 1 ml of TRIzol reagent used for initial 
homogenization. RNA was incubated for 10 min at room temperature and 
centrifuged at 12,000 x g for 10 min at 4°C. The RNA pellet was washed with 1 
ml of 70% ethanol per 1 ml of TRIzol reagent used for initial homogenization. The 
sample was centrifuged at 7,500 x g for 5 min at 4°C. The RNA pellet was re-
dissolved in DEPC treated water and stored at -70°C.  
RNA concentration and purity were measured spectroscopically by its 
absorbance at 260 nm and 280 nm. For the estimation of RNA concentration the 
below formula was employed. 
 
 
 
For the estimation of purity, A260/A280 ratio is calculated. The Ratio between 1.7 to 
2 is considered to be good RNA in our experiments. 
 
3.2.7 cDNA Synthesis 
Complementary DNA was synthesized from total RNA using Improm II Reverse 
Transcriptase (Promega, Germany). Two µg of total RNA was combined with 0.5 
µg of Oligo(dT)15 in nuclease-free water for a final volume of 5µl per RT reaction. 
This mixture was denatured at 70°C for 5 min followed by rapid cooling. After a 
short spin, the reverse transcription reaction mix was added and incubated at 
25°C for 5 min followed by incubation at 42°C for 1 hr. After synthesis, cDNA 
samples were either used immediately for PCR, or stored at -20˚C. 
 
RNA concentration = A260 x dilution x 40 µg/ml 
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Reverse Transcriptase reaction mix: 
 
 
 
 
 
 
 
 
 
3.2.8 Polymerase chain reaction 
To check for the presence of the gene of interest either in the animal tissue or 
primary cells, PCR was performed. PCR signal was amplified using the gene-
specific primers (as described) designed from the sequence available in the 
Genbank. For standard PCR, 20-23 bp long primers were designed, AT and GC 
content was checked and the difference in the melting temperature (Tm) between 
the forward and reverse primers was kept not more then 2-4ºC. The primer 
sequence was checked using the NCBI BLAST search for probable similarity with 
unrelated genes. PCR reaction was done in 0.2 ml thin wall tubes in T3 
Thermocycler. Negative control without template performed to check for self-
annealing of primer pair. PCR for cDNA without reverse transcriptase was also 
done to check the genomic DNA contamination. Each primer pair was checked 
with several annealing temperatures depending on the Tm of the primer pair to 
get a single and specific PCR band. 
 
3.2.9 Reverse Transcription-Polymerase Chain Reaction (RT-PCR) 
Semi quantitative RT-PCR was performed on cDNA samples by use of Taq 
polymerase (Promega, Germany). The reaction mixture included.  
ImProm-II™ 5X Reaction Buffer            4.0µl 
MgCl2, 25mM         2.0µl 
dNTP Mix, 10mM       1.0µl 
RNasin® Ribonuclease Inhibitor     1.0µl 
ImProm-II™ Reverse Transcriptase      1.0µl 
Nuclease-Free Water       6.0µl 
Final Volume        15.0µl 
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PCR master mix 
 
 
 
 
 
 
 
 
 
 
The tubes were flicked to mix and microfuged briefly before taking to the PCR 
machine. The thermal cycler’s program was as follows:  
 
 
 
 
 
 
For quantitative real-time RT-PCR analysis, 2 µl cDNA was placed into 50µl 
reaction volume containing SYBR Green PCR mix and sequence-specific 
oligonucleotide primers. In all cases forward and reverse primers were designed 
flanking an intron to make sure that the amplification signal comes from mRNA 
and not genomic DNA. 
Real time PCR master mix: 
 
 
 
 
 
Nuclease-Free Water       35.0µl 
10X polymerase reaction buffer       5.0µl 
MgCl2, 25mM           3.0µl 
PCR Nucleotide Mix, 10mM         1.5µl 
Forward Primer, 10µM         1.0µl 
Reverse Primer, 10µM        1.0µl 
Taq DNA Polymerase (5.0 units)        0.5µl 
Volume of RT reaction added        3.0µl 
Total PCR Volume        50.0µl 
Activation of HotstarTaq          95oC      2 min  
Denaturation      94oC    30 s 
Annealing     variable   30 s 
Extension     72oC    45 s 
Final extension    72oC    10 min 
Cycles    30-35
Nuclease-Free Water        16.0µl 
2x-Invitrogen Super Mix-Buffer      25.0µl 
ROX Reference Dye 50x         1.0µl 
MgCl2, 50mM            2.0µl  
Forward Primer, 10µM          1.0µl 
Reverse Primer, 10µM           1.0µl 
Volume of RT reaction added         1-3µl 
Total PCR Volume        50.0µl 
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The thermal cycle conditions used for all reactions were as follows:  
 
 
 
 
 
 
 
All real-time reactions were carried on ABI 7700 Sequence Detection System, 
and analysis was performed with the accompanying software. At the end of the 
PCR cycle, a dissociation curve was generated to ensure the amplification of a 
single product and the threshold cycle time (Ct values) for each gene was 
determined. Relative mRNA levels were calculated based on the Ct values and 
normalized to house keeping gene GAPDH. 
 
3.2.10 Agarose gel electrophoresis and PCR product purification 
PCR reactions were analyzed on 1% agarose gels in 1X TAE buffer, containing 1 
µg/ml ethidium bromide. Samples were prepared in 6x loading buffer (containing 
bromophenol blue dye) (MBI Fermentas). Gel was run in 1X TAE buffer for 60 
min at 80 V. Depending on the fragment size either GeneRuler 100bp DNA 
Ladder (1 kb) or GeneRuler DNA Ladder Mix (10 kb) (MBI Fermentas) used. 
DNA bands were visualised under UV-Transilluminator of Biometra system. 
For Semi-quantitative analysis of the PCR product, 10 – 20 µl of each reaction 
was used for electrophoresis. PCR signals were quantified in arbitary units (A.U) 
from optical density x band area. PCR signals were normalized to the GAPDH 
signal of the corresponding RT product to get a semi-quantitative estimate of the 
gene expression.  
The PCR product was purified with the QIAGEN gel extraction kit. Briefly, 
samples were loaded onto the gel. After gel run the corresponding bands were 
Activation of Taq           50oC    2 min  
Denaturation      95oC    10 min 
Denaturation II   95oC    10 s 
Annealing    60oC    5 s 
Cycles     40 
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excised and placed in 1.5 ml eppendorf tubes. Then add 300 µl of buffer QG for 
every 100 mg of gel. Incubated the gel slices in buffer at 50°C for minimum 15 
min. Then add 100 µl of isopropanol and placed in a QIAquick column. 
Centrifuge for 1 min at maximum speed. Then add 500 µl of buffer QG to the 
column and centrifuge again. After add 700 µl of buffer PE (containing ethanol) to 
the column and incubated for 5 min at room temperature. After centrifugation, 
Place the column into a fresh 1.5 ml recovery tube and added 30 µl of 
prewarmed buffer EB directly to the center of the column. Incubated for 10 min at 
room temperature and then centrifuged for 2 min at 12,000 rpm. Discarded the 
column and stored the DNA at -20°C. Further DNA was sent for sequencing. 
 
3.2.11 Western blotting 
Lung tissues were homogenized in 1x lysis buffer including protease inhibitor 
cocktail using a polytron tissue homogenizer. Later, samples were centrifuged at 
14,000 rpm in a pre-cooled centrifuge for 20 min. Supernatant was transferred 
into a fresh tube and measured for Protein concentration using Bradford assay 
with a bovine serum albumin standard. Lysates were aliquoted and stored at  
-80°C. In case of cells, confluent cells (6 well plates) were washed 1x with ice-
cold PBS and lysed in 100 µl of 1x lysis buffer. The cell lysate was gently mixed 
on a rotator for 15 min at 4°C. Lysate was then sonificated 3x10 sec in 
Ultrasonificator on ice followed by centrifugation. Supernatant was measured for 
Protein content as described above. 
When necessary, tissue and cell lysates containing equal amounts of protein 
were diluted with 5 x laemmli buffer (5:1 ratio of sample volume to buffer volume), 
boiled for 5 min at 95°C and subsequently pipette into the gel chambers for 
electrophoresis. The SDS PAGE was run at a constant voltage of 130 V for 1-1.5 
hr in 1 x running buffer. Upon completion of electrophoresis, the gel was 
removed from glass plates and allowed to soak in transfer buffer for 15 min. Gels 
were blotted onto nitrocellulose membrane using a semi dry technique. From 
bottom to top, the following layers were put in a blotting apparatus: three layers 
of whatman filter paper soaked followed by the nitrocellulose membrane, the gel, 
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and three layers of whatman paper soaked in 1x transfer buffer. Special attention 
was paid to eliminate all air bubbles between the layers. Electroblotting occurred 
for 1-1.5 hr at 100 mA per two gels. Afterwards, membranes were incubated in 
blocking solution for 1 hr at room temperature, and then incubated with a 
polyclonal rabbit DDAH1 (1:10,000), polyclonal goat DDAH2 (1:5000) or a mouse 
monoclonal GAPDH (1:5000) antibody overnight at 4°C. Later the membranes 
were washed (3x10 min) with wash buffer, incubated with the respective HRP-
conjugated polyclonal secondary antibodies for I hr at room temperature. Finally 
after three washing steps with wash buffer antibodies bound to the proteins on 
the membrane were detected using the “ECL Western Blotting Detection 
Reagent”, according to the manufacturer’s manual. 
 
3.2.12 Dot Blotting 
Samples were adjusted to 2 µg/L of protein and adsorbed on to a nitrocellulose 
membrane by using a dot blot apparatus. After non-specific blocking with 5% 
(w/v) lipid free milk, the membranes were incubated overnight with ADMA or 
SDMA antibody (1:1000) and then with HRP-conjugated goat anti-rabbit IgG 
(1:5000) for 1 hr at room temperature. Membranes were developed with ECL 
detection kit. The intensity of the dots were analyzed and quantified by Biometra 
image analysis software. Equal amount of protein loading was also confirmed by 
dot blotting membranes with an antibody against GAPDH.  
 
3.2.13 Immunohistochemical staining 
Paraffin-embedded lung tissue sectioned at a 3 µm thickness was deparaffinized 
in xylene and rehydrated in a graded ethanol series to phosphate-buffered saline 
(PBS, pH 7.2). Antigen retrieval was performed by pressure cooking in citrate 
buffer (pH 6.0) for 15 min. Immunohistochemical staining was performed using 
anti-ADMA, anti-SDMA, anti-DDAH1 and anti-DDAH2 antibodies in conjunction 
with an avidin-biotin-peroxidase kit. Briefly, the sections were pre-treated with 3% 
hydrogen peroxide to quench endogenous peroxidase activity. Then, the sections 
were incubated for 1h in 10% normal goat serum to block non-specific binding 
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sites prior to the application of primary antibodies. Sections were then incubated 
overnight at 4°C with the primary antibodies (Abs). Biotinylated anti-rabbit or anti-
goat immunoglobulins (Ig) and avidin-biotinylated enzyme complex (ABC kit) 
were applied according to the manufacturer's instructions. After each incubation 
step, sections were washed briefly in PBS. Development of the reaction was 
carried out with VIP substrate for horseradish peroxidase for 10 min. Finally, 
sections were counterstained with methylgreen and dehydration using graded 
alcohol and xylene. The sections were then cover slipped and allowed to dry 
overnight. 
 
3.2.14 Histological analysis 
After dehydration in automatic vacuum tissue processor and paraffin embedding, 
5µm sections were stained for Elastin-Nuclear Fast Red to assess the medial 
wall thickness. For quantitative analysis of the degree of muscularization of small 
pulmonary arteries a double staining for alpha smooth muscle actin and von 
Willebrand (vWF) factor was performed. For visualization of the alpha smooth 
muscle actin the Vector Vip substrate kit for horseradish peroxidase and for 
visualization of the anti-vWF antibody 3, 3′-diaminobenzidine (DAB) substrate 
was used. Nuclear counterstaining was done with methyl green. 
 
3.2.15 Measurement of ADMA and SDMA 
L-arginine, ADMA, and SDMA were simultaneously analyzed by high-
performance liquid chromatography (HPLC). Briefly, plasma was mixed with 
internal standard and PBS and applied to Oasis MCX solid-phase extraction 
cartridges. After washing with Hydrochloric acid and methanol, amino acids were 
eluted with 1.0 ml of concentrated ammonia/water/methanol (10/40/50). The 
solvent was evaporated under a stream of nitrogen and the amino acids were 
derivatized with o-phthaldialdehyde reagent containing 3-mercaptopropionic acid. 
The derivatized amino acids were separated by isocratic reversed-phase 
chromatography on a C18 column at a column temperature of 30°C using a 
mobile phase consisting of potassium phosphate buffer (50 mmol/L ; pH 6.5), 
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containing 8.7% acetonitrile at a flow-rate of 0.3 ml/min. Fluorescence detection 
was performed at excitation and emission wavelengths of 340 and 455 nm, 
respectively. The stable derivatives were separated with near baseline resolution. 
Using a sample volume of 0.2 ml, linear calibration curves were obtained with 
limits of quantification of 0.08 µM for L-arginine and 0.01 µM for ADMA and 
SDMA.  
 
3.2.16 DDAH activity assay 
DDAH activity was assayed by determining L-citrulline formation in tissue 
homogenates by colorimetric method in 96-well microtiter plates. 
Lung tissues were homogenized using polytron homogenizer and centrifuged at 
13000 rpm to separate soluble material from insoluble cell debris. Aliquots of 
lysates were assayed for DDAH activity with a colorimetric assay in 96-well 
microtiter plates for citrulline production. For colorimetric assays, 55 µl of tissue 
lysate in 100 mM Na2HPO4, pH 6.5 was incubated at 37 °C for 60 min with 5 µl of 
containing 80 mM L-NMMA, ADMA, SDMA or L-arginine, or with buffer alone. 
After incubation, the reaction was stopped, and the activity was calculated after 
measuring the concentration of L-citrulline with a chromogenic reaction that 
specifically determines ureido groups. The calibration curve was obtained using 
L-Cit concentrations between 0 and 400 µM. One unit of enzyme activity was 
defined as the amount of enzyme catalyzing the formation of 1 µmol/L L-citrulline 
per min at 37°C. As the assay blank, the homogenate was subjected to the same 
determination process of DDAH activity in the absence of ADMA to provide the 
background values. Genuine DDAH activity was obtained by experimental data 
subtracting the background values. 
 
3.2.17 NOx measurements 
Plasma samples were stored at –80°C for less than 2 weeks before analysis. At 
the time of NOx assay, plasma samples were ultrafiltered (30 kDa molecular 
weight cut-off) and centrifuged at 1000 g for 60 min in order to remove 
hemoglobin, which is known to interfere with spectrophotometric measurements. 
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NOx concentration in different dilutions of plasma ultrafiltrate was determined by 
using a reagent kit (Cayman, Ann Arbor, USA) based on the Griess reaction, 
which consists of three main steps: 1) enzymatic conversion of nitrate to nitrite by 
means of nitrate reductase in the presence of 5 mmol/l NADPH; 2) incubation 
with Griess reagent (0.1% N- (1-naphthyl) ethylenediamine dihydrochloride and 
1% sulfanilamide in 2.5% H3PO4) for 10 min at 25°C to convert nitrite into a 
chromophore compound; 3) quantitative estimation of nitrite concentration by 
spectrophotometric measurement of the absorbance at 540 nm. Standards for 
calibration curves were prepared with nitrate and taken through the full assay 
procedure. The results were expressed as µmol/l of NOx. 
 
3.2.18 Culture of human HUVEC cells 
ECs were isolated from human umbilical veins (HUVEC) and grown in EGM-2 
culture medium including supplements and growth factors by the vendor 
(Cambrex Bio Science, Walkersville, USA) at 37°C in a CO2 incubator. For 
assessment of cytokine mediated DDAH expression, HUVECs at passage 3 or 
less were grown in 6-well plates and after  95% confluence incubated with 10 
ng/mL interferon gamma (IFNγ) or 10 ng/mL tumor necrosis factor-α (TNF-α) or 
both. After 24 hrs cells were scrapped with protein lysis buffer.  
 
3.2.19 Data analysis 
All data are given as mean ± SEM. Differences between the groups were 
assessed by student’s t test with a p value < 0.05 regarded to be significant. 
 
Results 
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4. Results 
 
4.1 IPAH patients 
4.1.2 IPAH patient characteristics 
Patient characteristics are given in Table 4. Blood from eleven patients with IPAH 
(all NYHA class III and IV) was collected and L-arginine, ADMA and SDMA levels 
were determined. Mean pulmonary artery pressure was 52.7±3.2 mmHg and 
cardiac index 2.19±0.11 l/min m2 with the pulmonary vascular resistance index 
(PVRI) calculated at 1360±104 dyne s cm-5 m-2. The six-minute-walk distance 
was 318±28 m.  
 
Patient NYHA SMW HR mSAP mPAP PAWP CVP SVRI PVRI CI SaO2 SvO2 
  [m] beats/min [mmHg] [mmHg] [mmHg] [mmHg] [dyne s cm-5 m2 ] [dyne s cm-5 m2 ] [l/min m2] [%] [%] 
1 3 432 90 97 60 5 5 1968 1176 2.17 99.1 69.3 
2 3 401 73 112 64 10 7 1683 866 2.92 96.6 73.2 
3 3 333 94 86 56 7 18 1397 1104 1.87 92.6 65.3 
4 3 347 73 85 62 11 11 1691 1166 2.25 83.3 62.2 
5 3 290 74 74 31 6 6 3425 1259 1.59 96.5 65.9 
6 4 168 63 67 51 10 8 2517 1749 1.87 86.2 57.9 
7 3 415 82 88 63 11 11 2898 1957 2.13 80.0 64.2 
8 4 145 80 125 50 8 9 3811 1380 2.43 92.2 57.9 
9 3 370 84 102 47 8 7 2831 1162 2.68 98.6 74.8 
10 3 302 64 99 39 5 4 3613 1293 2.10 92.2 56.0 
11 3 298 86 135 57 8 7 4854 1858 2.11 89.8 64.2 
Mean  318 78 97.3 52.7 8.1 8.5 2789 1360 2.19 91.6 64.6 
SEM  28 3 6.2 3.2 0.7 1.2 323 104 0.11 1.9 1.8 
  
Table 4: IPAH patient characteristics. NYHA = New York Heart Association functional classes; 
SMW = six minute walk testing (according to the guidelines of the American Thoracic Society); 
HR = heart rate; mSAP = mean systemic arterial pressure; mPAP = mean pulmonary artery 
pressure; PAWP = pulmonary artery wedge pressure; CVP = central venous pressure; SVRI = 
systemic vascular resistance index; PVRI = pulmonary vascular resistance index; CI = cardiac 
index; SaO2 = arterial oxygen saturation; SvO2 = venous oxygen saturation. 
 
4.1.2 ADMA and SDMA elaboration in IPAH patients 
We have observed elevated plasma levels of ADMA and SDMA in patients with 
IPAH. As compared to healthy subjects, ADMA was increased from 0.48±0.04 to 
1.06±0.06 µmol/l and SDMA from 0.53±0.07 to 1.46±0.24 µmol/l (Figure 7).We 
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also have found that plasma levels of L-arginine decrease significantly in IPAH 
patients compared to healthy subjects. Most impressively, L-arginine/ADMA ratio 
is also reduced in IPAH patients. 
 
                                  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Measurement of ADMA and SDMA levels from plasma of healthy subjects and 
patients with IPAH.  Free ADMA and SDMA were measured by reverse phase HPLC from 
plasma of healthy subjects and patients with IPAH. Values are means ± SEM and represent 11 
patients and 8 healthy subjects. *, p<0.05 versus healthy subjects. 
 
4.1.3 Localization of dimethylarginines in lungs from patients with IPAH 
Immunohistochemical staining for asymmetric and symmetric dimethylated 
arginine proteins within human lung tissue is shown in Figure 8. In normal human 
lung, immunoreactivity to specific asymmetric and symmetric dimethylated 
arginine proteins was observed in the bronchiolar ciliated and terminal cuboidal 
epithelium, type I and type II alveolar epithelium, arterial and capillary 
endothelium, and alveolar macrophages with very little difference in their 
distribution throughout the lung. In comparison, the specific asymmetric and 
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symmetric dimethylated arginine proteins immunoreactivity was preferentially 
increased in the pulmonary endothelium of lung specimens from patients with 
IPAH. Immunostaining was more marked in those areas with more severe medial 
hypertrophy, as well as in plexiform lesions. In contrast, no staining difference 
was observed in alveolar or bronchiolar epithelium.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Immunostaining of dimethylated arginine proteins in lungs from healthy donors 
and patients with IPAH. Lung sections from a healthy donor and IPAH patient with anti-ADMA 
and anti-SDMA shows immunoreactivity of asymmetric and symmetric dimethylated arginine 
proteins in pulmonary arterial endothelial cells and in alveolar epithelial cells. Æ, indicates 
endothelium; h, indicates epithelium. Scale bar: 100µm; PA: pulmonary artery.  
 
4.1.4 Increased biosynthesis of dimethylarginines in lungs from patients 
with IPAH 
The tissue levels of asymmetric and symmetric dimethylated arginine proteins 
were quantified by dot-blotting. Significant higher degree of dimethylation was 
demonstrated in IPAH compared to healthy donors (Figure 9). As compared to 
donor lungs, asymmetric and symmetric dimethylated arginine proteins were 
upregulated 210 ±18 % and 240 ± 26% respectively, in IPAH lungs. 
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Figure 9: Dot blot analysis of dimethylated arginine proteins in lungs from healthy donors 
and patients with IPAH. (A) Dot blotting with anti-ADMA and anti-SDMA antibodies and 
subsequent (B) quantification of asymmetric and symmetric dimethylated arginine proteins in lung 
homogenates from healthy donors and patients with IPAH. Values (means ± SEM) are expressed 
as percentage of expression found in donor tissue (n=7). *, p<0.05 versus donor. 
 
4.1.5 Localization of DDAH isoforms in lungs from patients with IPAH 
Immunohistochemical localization of DDAH isoforms within human lung tissue is 
shown in Figure 10. Immunostaining was detected strongly in the endothelium of 
all generations of arteries, with a weak or no immunostaining for DDAH1 and 
DDAH2 expression in either vascular smooth muscle or adventitial cells. 
Additional immunostaining was detected in both alveolar (low level) and 
bronchiolar epithelium; specific and intense staining for DDAH1 was observed 
particularly on the apical surface of the bronchiolar epithelium, whereas DDAH2 
dominated in basal cells of the bronchiolar epithelium. Neither airway smooth 
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muscle nor adventitial cells exhibited DDAH1 or DDAH2 immunostaining. When 
compared to controls, a marked reduction or even absence of DDAH2 
immunoreactivity was observed in the endothelium of sections from patients with 
pulmonary arterial hypertension. In contrast, no significant difference was 
observed in DDAH1 immunostaining density between IPAH and healthy donor 
lungs. There was no immunostaining observed in the negative control sections. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Immunostaining of DDAH isoforms in healthy donor and IPAH patient lungs. 
Lung sections from a healthy donor show immunoreactivity of DDAH1 and DDAH2 in pulmonary 
arterial endothelial cells and in alveolar epithelial cells. Lung sections from patients with IPAH 
even show strong immunoreactivity of DDAH1 with in pulmonary arterial endothelial cells and in 
alveolar epithelial cells but with no detectable immunostaining of DDAH2 in endothelial layer of 
pulmonary arteries.  Æ, indicates endothelium; h, indicates epithelium Scale bar: 100µm; PA: 
pulmonary artery. 
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4.1.6 Decreased metabolism of dimethylarginines in lungs from patients 
with IPAH 
4.1.6.1 mRNA expression of DDAH isoforms  
DDAH1 mRNA levels were unchanged, while DDAH2 expression was 
significantly reduced, when comparing IPAH lungs to healthy donor lungs (Figure 
11). DDAH2 was significantly downregulated by a factor of 2.12±0.38 fold in 
lungs from IPAH patients compared to healthy donors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Real time RT-PCR analysis of DDAH isoforms from healthy donor and IPAH 
patient lungs. Relative quantification of mRNAs encoding for (A) DDAH1 and (B) DDAH2 related 
to the housekeeping gene GAPDH was undertaken by real-time RT-PCR. (C) Gel picture 
showing DDAH1 and DDAH2 expression in total RNA isolated from healthy donor and IPAH 
patient lung tissues.  All values are given as mean ± SEM (n=3). *, p<0.05 versus donor.  
 
4.1.6.2 Protein expression of DDAH isoforms  
Western blot analysis of lung homogenates using a polyclonal DDAH1 antibody 
showed that the 34-kDa DDAH1 protein was strongly expressed in the donor 
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lungs and remains unaltered or change insignificantly in the IPAH patient lungs 
(Figure 12A, B). Densitometry revealed that the IPAH patient lungs expressed 
10% less DDAH1 protein than those of donor lungs. 
In contrast, Western blot analysis of lung homogenates using a polyclonal 
DDAH2 antibody revealed a band at 42-kDa DDAH2 protein and was significantly 
reduced in the IPAH patient lungs as compared to donor lungs. Densitometry 
revealed 77% reduction in DDAH2 expression compared to healthy donor lungs 
(Figure 12A, B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Western blot analysis of DDAH isoforms in lungs from healthy donors and 
patients with IPAH.  (A) Western blot analysis was performed with anti-DDAH1 and anti-DDAH2 
antibodies in lung homogenates from healthy donors and patients with IPAH. The specific 
antibodies recognize protein at a molecular weight of 34kDa and 42kDa. (B) Quantification of the 
DDAH1 and DDAH2 signal in each group. Values (means ± SEM) are expressed as percentage 
of expression found in donor tissue (n=7). *, p<0.05 versus donor. 
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In addition, a significant negative correlation between DDAH II expression 
(normalized to GAPDH) and mean pulmonary arterial pressure of the 
transplanted IPAH patients (Figure 13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Correlation of DDAH2 expression to mean PAP of 5 transplanted IPAH patients. 
DDAH2 expression is given in arbitary units and normalized to GAPDH expression. Mean 
pulmonary arterial pressure (mPAP) is given in mmHg. 
 
4.2 Monocrotaline (MCT) treated rats 
4.2.1 Hemodynamics and right heart hypertrophy 
Monocrotaline (MCT) treatment caused a marked increase in right ventricular 
systolic pressure (64.5±5.7 mm Hg) when compared to saline injected control 
animals (22.4±1.7 mm Hg) (Figure 14) without a significant difference in systemic 
arterial pressure. The ratio of right ventricular to left ventricular plus septal weight 
(RV/LV+S), an indirect index of severity of pulmonary hypertension, was 
significantly increased after monocrotaline administration (0.29±0.04 to 
0.52±0.03). The MCT-treated groups had significantly lower BW than time-
matched control animals. Eighty percent (8 of 10) animals survived after MCT 
treatment. The hemodynamic changes were accompanied by significant media 
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hypertrophy of pulmonary vessels, increased distal pulmonary artery 
muscularization and a subsequent reduction in the number of peripheral 
pulmonary arteries. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Hemodynamics, gas exchange and right heart hypertrophy in control and MCT-
induced pulmonary hypertensive rats. Right ventricular systolic pressure (RVPsys, in mmHg), 
systemic arterial pressure (SAP, in mmHg), cardiac index (CI, in ml/min 100 g bodyweight), right  
to left ventricular weight ratio (RV/LV+S) and arterial oxygenation (PaO2/FiO2) are given (mean ± 
SEM of 8 independent experiments each). *, p<0.05 versus control.  
 
4.2.3 Increased plasma levels of ADMA and SDMA in MCT-PAH rats 
Plasma levels of ADMA were four-fold increased (0.37±0.08 versus 1.60±0.15 
µmol/l), and SDMA levels seven fold increased from 0.41±0.10 to 2.74±0.21 
µmol/l in MCT-treated rats compared to control rats (Figure 15).  
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Figure 15: Plasma concentrations of ADMA and SDMA from control and MCT-PAH rats. 
Plasma ADMA and SDMA levels were measured by HPLC in saline treated (control) rats and rats 
4 weeks after a single injection of monocrotaline (MCT). Values are given as mean ± SEM (n=8). 
*, p<0.05 versus control. 
 
4.2.3 Localization of dimethylated arginine proteins in MCT-PAH rat lungs 
Immunostaining of asymmetric and symmetric dimethylated arginine proteins in 
rat lung tissue results were well in line with those of the human lung tissue. In the 
control rat lungs, specific immunoreactivity of the asymmetric and symmetric 
dimethylated arginine proteins was observed in the bronchiolar ciliated and 
terminal cuboidal epithelium, type I and type II alveolar epithelium, arterial and 
capillary endothelium, and alveolar macrophages with very little difference in their 
distribution throughout the lung. However, MCT - exposure caused an increased 
immunostaining density of asymmetric and symmetric dimethylated arginine 
proteins in pulmonary arteries (Figure 16).  
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Figure 16: Immunoreactivity of dimethylarginines in lungs from control rats and rats with 
MCT-PAH. Immunostaining of control rat lung sections with anti-ADMA and anti-SDMA show a 
moderate immunoreactivity to asymmetric and symmetric dimethylated arginine proteins in 
pulmonary arterial endothelial cells and in alveolar epithelial cells. Distinctly, a much stronger 
immunoreactivity, especially in the endothelial layer of pulmonary arteries was illustrated in MCT-
PAH rat lung sections. Æ, indicates endothelium; h, indicates epithelium. Scale bar: 100µm; PA: 
pulmonary artery 
 
4.2.4 Augmentation of dimethylated arginine proteins in MCT-PAH rat lungs 
The tissue levels of asymmetric and symmetric dimethylated arginine proteins 
were detected by dot-blot and a significant higher degree of dimethylation was 
demonstrated in MCT-treated rats (Figure 17A, B). As compared to control rat 
lungs, asymmetric and symmetric dimethylated arginine proteins were 
upregulated 218 ± 17 % and 268 ± 19% respectively, in MCT-PAH lungs. 
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Figure 17: Dot blot analysis of dimethylated arginine proteins in lungs taken from control 
rats and rats with MCT-PAH. (A) Dot blotting with anti-ADMA and anti-SDMA antibodies and 
subsequent (B) quantification of asymmetric and symmetric dimethylated arginine proteins in lung 
homogenates from control rats and rats with MCT-PAH. Values (means ± SEM) are expressed as 
percentage of expression found in control tissue (n=4). *, p<0.05 versus control. 
 
4.2.5 Localization of DDAH isoforms in MCT rat lungs 
Similar to ADMA and SDMA, DDAH isoform (Figure 18) immunostaining of rat 
lung tissue results were well in line with those of the human lung tissue. As 
compared to humans, a greater degree of DDAH1 and DDAH2-like 
immunostaining was seen in vascular smooth muscle cells of the control rat 
lungs. Interestingly, a drastic reduction in DDAH2 immunoreactivity in pulmonary 
endothelium of MCT-PAH rat lungs was demonstrated when compared with 
control tissues. In contrast, DDAH1 immunoreactivity remained unaltered.  
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Figure 18: Immunoreactivity of DDAH isoforms in lungs from control rats and rats with 
MCT-PAH.  Lung sections from a control rat demonstrate a moderate to strong DDAH1 and 
DDAH2 immunoreactivity in pulmonary arterial endothelial cells, smooth muscle cells and in 
alveolar epithelial cells. Lung sections from rats with MCT-PAH even show strong 
immunoreactivity of DDAH1 with in pulmonary arterial endothelial cells and in alveolar epithelial 
cells but with no detectable immunostaining of DDAH2 in endothelial layer of pulmonary arteries. 
Æ, indicates endothelium; h, indicates epithelium. Scale bar: 100µm; PA: pulmonary artery. 
 
4.2.6 MCT inhibits expression of DDAH isoforms at mRNA level 
The expression of DDAH1 at the mRNA level was unchanged, while DDAH2 was 
significantly decreased in MCT-treated rat lungs (Figure 19). As compared to 
control rat lungs DDAH2 expression was significantly decreased by a fold of 
3.12±0.39 in MCT-treated rats. 
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Figure 19: Real time RT-PCR analysis of DDAH isoforms from control and MCT-PAH rat 
lungs. Relative quantification of mRNAs encoding for (A) DDAH1 and (B) DDAH2 related to the 
housekeeping gene GAPDH was undertaken by real-time RT-PCR. (C) Gel picture showing 
DDAH1 and DDAH2 expression in total RNA isolated from control and MCT-PAH rat lung tissues.  
All values are given as mean ± SEM (n=3). *, p<0.05 versus control.  
 
4.2.7 MCT inhibits expression of DDAH isoforms at protein and activity 
level 
MCT-exposure caused significant changes in dimethylarginine metabolism. 
DDAH isoform expression and activity was significantly altered. DDAH1 protein 
expression was reduced by 12% (Figure 20A, B). In contrast, DDAH2 protein in 
lungs from monocrotaline-treated animals was reduced by 48% (Figure 20B, D). 
Total DDAH activity was reduced by 79% (Figure 21). 
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Figure 20: Expression of DDAH2 in lung homogenate from control and MCT-PAH rats.  
(A,B) Western blot analysis was performed with anti-DDAH1 and anti-DDAH2 antibodies in lung 
homogenates from control rats and rats with MCT-PAH. The specific antibodies recognize protein 
at a molecular weight of 34kDa and 45kDa. (C,D) Quantification of the DDAH1 and DDAH2 signal 
in each group. Values (means ± SEM) are expressed as percentage of expression found in 
control tissue (n=4). *, p<0.05 versus control. 
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Figure 21: Activity of DDAH2 in lung homogenate from control and MCT-PAH rats. DDAH 
enzyme activity was determined by in vitro assay of crude lung homogenates from control and 
MCT-PAH rats. DDAH activity was assayed by the conversion of L-citrulline from ADMA. One unit 
of the enzyme was defined as the amount that catalyzed the formation of 1 mM L-citrulline from 
ADMA per minute at 37°C. Values (means ± SEM) are expressed as percentage of expression 
found in control tissue (n=4). *, p<0.05 versus control. 
 
4.2.8 TNF-α and IFN-γ mediates DDAH dysregulation 
HUVEC cells treatment with proinflammatory cytokines, TNF-α, IL-1β and IFN-
γ dramatically modulated DDAH2 expression. TNF-α and IFN-γ treatment 
reduced DDAH2 expression by 53% and 41% respectively. In contrast IL-
1β induced DDAH2 expression by 138 % (Figure 22)  
 
 
 
 
 
 
 
 
 
Figure 22: DDAH modulation by cytokines. (A) Western blot analysis of DDAH2 and GAPDH 
expression in HUVEC cells treated with TNF-α, IL-1β and IFN-γ (10 ng/ml)  for 24 hrs. (B) 
Quantification of the DDAH2 signal related to the house keeping gene GAPDH in each group. 
Values (means ± SEM) are expressed as percentage of expression found in control cells (n=3). *, 
p<0.05 versus control. 
 
4.3 Chronic effects of aerosolized tolafentrine in MCT treated rats 
4.3.1 Acute vasodilatory effects  
Aerosolized tolafentrine reduced right ventricular systolic pressure [RVSP] in 
MCT[28d] rats in a dose-dependent manner (Figure 23). As depicted, this 
pulmonary vasodilatation was accompanied by less pronounced decrease in 
systemic arterial pressure. 
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Figure 23: Immediate vasodilatory effects of inhaled tolafentrine in MCT-induced PAH. 
Monocrotaline (MCT[28d]) treated animals received tolafentrine over an inhalation period of 5 min 
subsequent to catheterization. The decrease in right ventricular systolic pressure (RVSP, in 
mmHg) and systemic arterial pressure (SAP, in mmHg) in response to the vasodilatory treatment 
is given. All values are given as mean ± SEM (n=8). 
 
4.3.2 Hemodynamics 
After injection of monocrotaline, pulmonary hypertension developed (right 
ventricular systolic pressure on day 28 = 66.5±3.2 mm Hg (n=11), as compared 
to 25.9±4.0 mm Hg in the control animals (n=10)) (Figure 24). No significant 
changes in systemic arterial pressure occurred. As compared to control animals 
(36.5±3.5 ml/min 100 g body weight), cardiac index was slightly decreased on 
day 28 (31.8±1.3 ml/min/100 g body weight). Aerosolized tolafentrine treatment 
(625 ng/kg per minute) for 2 weeks significantly lowered right ventricular pressure 
to 43.4±2.1 mmHg.  
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Figure 24: Influence of inhaled tolafentrine on hemodynamics in MCT–induced PAH. Right 
ventricular systolic pressure (RVSP, in mmHg), systemic arterial pressure (SAP, in mmHg), 
cardiac index (CI, in ml min-1 100 g body weight-1) and pulmonary vascular resistance index 
(PVRI, in mmHg min ml-1 100 g body weight-1) are given. Tolafentrine was applied by repetitive 
inhalations from day 14 to day 28. All values are given as mean ± SEM (n=9). *, p<0.05 versus 
control; †, p<0.05 versus MCT[28d]. 
 
Both arterial PO2 and central venous oxygen saturation (SvO2) decreased on 
MCT treatment. The MCT treated groups had significantly lower BW than time 
matched control animals. The decrease in arterial PO2 and SvO2 in response to 
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MCT treatment was normalized (~70%) in the tolafentrine-treated animals (Figure 
25).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: Influence of long-term treatment with inhaled tolafentrine (Tola) on BW and 
blood gases in MCT-induced PAH. Animals were investigated 28 days after MCT treatment 
(MCT[28d]). BW (in g), PaO2/ FIO2 (in mm Hg), and SvO2 (in %) are given. Tolafentrine was 
applied by repetitive inhalations from day 14 to day 28 (MCT[28d]/Tola). Control animals received 
sham injection of saline. All values are given as mean ± SEM (n=9).  *, p<0.05 versus control. 
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Four weeks after injection of MCT, animals demonstrated significant right heart 
hypertrophy, as indicated by an increase in the right ventricular to left ventricular 
plus septum weight ratio (RV/LV+S) from 0.29±0.02 (control animals) to 0.53± 
0.04. Inhaled tolafentrine prevented and slightly reversed established right 
ventricular hypertrophy (MCT[28d]/Tola = 0.47±0.03) (Figure 26). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26: Influence of inhaled tolafentrine on right heart hypertrophy. Right to left 
ventricular plus septum ratio (RV/LV+S) of different treatment groups is given. Tolafentrine was 
applied by repetitive inhalations from day 14 to day 28.  All values are given as mean ± SEM 
(n=9). *, p<0.05 versus control; †, p<0.05 versus MCT[28d]. 
 
4.3.4 Histopathology 
Elastin staining and subsequent morphometric analysis of pulmonary arteries 
demonstrated a markedly increased medial wall thickness in both the MCT[28d] 
and the MCT[28d] groups, when compared with the saline-treated group. Most 
impressively, medial wall thickness was significantly reduced by long term 
treatment of aerosolized tolafentrine (Figure 27). The hemodynamic changes 
were accompanied by significant media hypertrophia of pulmonary vessels that 
was reversed by long term treatment of aerosolized tolafentrine (Figure 27). 
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Figure 27: Effect of inhaled tolafentrine on the degree of muscularization and on the 
medial wall thickness of small pulmonary arteries. Immunohistochemical analysis of lung 
sections originating from saline (Control), monocrotaline (MCT[28d]) and monocrotaline plus 
tolafentrine (MCT[28d]/Tola) treated animals. Staining was undertaken for von willebrand-factor 
(brown; endothelial cells) and alpha smooth muscle actin (purple; smooth muscle cells) as well as 
elastin.  Scale bar: 20 µm. 
 
4.3.5 Effect on methylarginine production 
Tolafentrine treatment of MCT rats for 2 weeks caused a substantial and 
significant decrease in the plasma ADMA and SDMA levels. Plasma ADMA 
levels in the tolafentrine lungs is decreased from 1.65±0.15 to 0.31±0.04 
compared to MCT treated rats (MCT[28d]) alone (Figure 28). In addition, the 
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absolute concentration of SDMA decreased from 2.75±0.35 to 0.37±0.07, 
suggesting decreased protein turnover in tolafentrine treated MCT lungs. 
 
 
 
 
 
 
 
 
 
 
 
Figure 28: Effect of tolafentrine on plasma monocrotaline induced ADMA and SDMA levels. 
(A) Plasma ADMA and (B) SDMA levels of rats treated with saline (Control), monocrotaline 
(MCT[28d]) and monocrotaline plus tolafentrine (MCT[28d]/Tola) treated animals. All values are 
given as mean ± SEM (n=8). *, p<0.05 versus control; †, p<0.05 versus MCT[28d]. 
 
4.3.6 Effect of tolafentrine on DDAH expression 
DDAH2 mRNA levels that were significantly reduced by MCT treatment were 
upregulated with 2 weeks treatment of tolafentrine (Figure 29). Further, western 
blot analysis confirmed that DDAH2 protein expression was also increased by 
tolafentrine treatment of MCT treated (MCT[28d]) rats (Figure 30). Interestingly, the 
DDAH2 expression at both mRNA and protein level was near normalized to 
control rat lung DDAH2 expression.  
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Figure 29: Effect of tolafentrine on DDAH2 mRNA expression. (A) mRNA expression and 
subsequent (B) quantification of DDAH2 in lung homogenates of rats treated with saline (Control), 
monocrotaline (MCT[28d]) and monocrotaline plus tolafentrine (MCT[28d]/Tola) treated animals. All 
values are given as mean ± SEM (n=3). *, p<0.05 versus control; †, p<0.05 versus MCT[28d]. 
 
 
 
 
 
 
 
 
 
Figure 30: Effect of tolafentrine on DDAH2 protein expression. (A) Immunoblots and 
subsequent (B) densitometric quantification of DDAH2 in lung homogenates of rats treated with 
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saline (Control), monocrotaline (MCT[28d]) and monocrotaline plus tolafentrine (MCT[28d]/Tola) 
treated animals. All values are given as means ± SEM (n=4). *, p<0.05 versus control; †, p<0.05 
versus MCT[28d]. 
 
4.3.7 Effect of tolafentrine on DDAH Activity 
Figure 30 shows the effects of tolafentrine on DDAH activity of MCT lungs. As 
expected, DDAH activity was decreased by 4 fold after MCT treatment as 
compared to controls. 2 weeks treatment of MCT rats with tolafentrine restored 
DDAH activity nearly to a normal level compared with MCT (MCT[28d]) group 
(Figure 31). But tolafentrine treatment of control lungs per se did not affect DDAH 
activity compared with control lungs.  
 
 
 
 
 
 
 
 
 
Figure 31: Effect of tolafentrine on DDAH activity. DDAH enzyme activity was determined by 
in vitro assay of crude lung homogenates from rats treated with saline (Control), monocrotaline 
(MCT[28d]) and monocrotaline plus tolafentrine (MCT[28d]/Tola) treated animals. All values are 
given as mean ± SEM (n=4). *, p<0.05 versus control; †, p<0.05 versus MCT[28d]. 
 
4.3.8 Effect of tolafentrine on NO synthesis 
In parallel to the alterations in DDAH activity, tolafentrine also induced 
statistically significant increase in plasma nitrite/nitrate (NOx) levels (Figure 32). 
Four weeks MCT treated rats showed a remarkable decrease in NOx levels from 
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14.8±4.7 to 3±1.28 µmol/l in control rats. Most impressively, treatment of MCT 
rats with tolafentrine significantly elevated NOx levels from 3±1.28 to 12.9±3.4 
µmol/l and nearly normalized to control plasma NOx values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32: Effect of tolafentrine on nitrite/nitrate (NOx) levels. Plasma nitrite/nitrate levels 
was determined by griess reagent from rats treated with saline (Control), monocrotaline (MCT[28d]) 
and monocrotaline plus tolafentrine (MCT[28d]/Tola) treated animals. All values are given as mean 
± SEM (n=8). *, p<0.05 versus control; †, p<0.05 versus MCT[28d]. 
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5 Discussion 
 
5.1 Increased levels and reduced catabolism of asymmetric and symmetric 
dimethylarginines in pulmonary hypertension 
An increase in levels of ADMA, an endogenous inhibitor of nitric oxide synthases 
is known to contribute to the pathogenesis and progression of various 
cardiovascular diseases associated with endothelial dysfunction. Interestingly, 
Increased plasma concentrations of ADMA (1.06 µmol/L) were also observed in 
the currently studied IPAH patients as compared to levels in healthy subjects 
ranging between 0.30 to 0.42 µmol/L. This increase is comparable with values 
obtained from other conditions associated with endothelial dysfunction such as in 
patients with pulmonary hypertension associated with congenital heart disease 
(0.55µmol/L), hypercholesterolemia (0.60µmol/L), Type 2 diabetes mellitus 
(1.59µmol/L) and hyperhomocystinemia (1.6µmol/L) (92-95).  
 
In the present investigation, we employed monocrotaline for induction of severe 
pulmonary hypertension in rats, as documented by a threefold increase in right 
ventricular systolic pressure and right heart hypertrophy (105). Similar to 
previous observations in hypoxia-induced experimental pulmonary hypertension 
(106), a marked increase in plasma ADMA levels was noted in the MCT treated 
animals. Such enhanced ADMA levels may well result in substantial NOS 
inhibition, and it is in line with this reasoning that reduced NO production is an 
underlying mechanism responsible for impaired endothelium-dependent 
relaxation, that was previously illustrated in response to MCT treatment 
(107,108).  
 
Moreover, the main endothelial ADMA metabolizing enzyme, DDAH2, was found 
to be drastically reduced in response to MCT treatment, as shown on the mRNA, 
protein and functional level and by immunohistochemistry. This loss of DDAH2 
activity may result in local (intracellular) ADMA levels even surpassing those in 
the blood compartment, thereby aggravating the suppression of endothelial NO 
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formation. This notion is in line with previous studies in hypoxic lungs, where 
reduced DDAH expression was also observed (106). The molecular mechanisms 
underlying DDAH suppression in hypoxia- and MCT-induced pulmonary 
hypertension remain to be elucidated, but may include the impact of oxidative 
stress (96), viral infection (97) and the nuclear receptor PPARγ on the 
transcriptional and translational control of DDAH (109). Recently, several 
polymorphisms within the DDAH2 promoter were identified which could be a risk 
factor for cardiovascular diseases (110). In our study, we found that protein 
levels of DDAH were affected by pro-inflammatory cytokines, TNF-  and IFNγ. 
DDAH expression of endothelial cells was decreased to almost 50% of baseline 
values by incubation with TNF-  and IFNγ. The study nicely corroborates with 
human IPAH patients that had an aggravated production of TNF-alpha as well as 
with MCT-induced PAH rats causing endothelial dysfunction. 
 
Interestingly, the plasma levels of SDMA also markedly increased in MCT-treated 
rats. The role of SDMA in vascular dysfunction is not yet clear, however, since 
SDMA is an inhibitor of the human cationic amino acid transporter hCAT-2B (80), 
it may indirectly inhibit NO synthesis by interfering with arginine uptake. Thus, 
enhanced SDMA levels are to be expected to synergize with enhanced ADMA 
levels in causing endothelial NOS inhibition, along with a substantial amount of 
substrate depletion by transstimulation, which may well contribute to prolonged 
pulmonary vasoconstriction and lung vascular remodeling in the MCT model.  
 
As demonstrated by dot-blot and immunohistochemistry, asymmetric and 
symmetric dimethylated arginines are highly increased in both human lung tissue 
of idiopathic pulmonary arterial hypertension and rat tissue of monocrotaline 
induced pulmonary hypertension. The source of asymmetric and symmetric 
dimethylated arginines are protein arginine N-methyltransferases (PRMTs) which 
were shown to be upregulated in response to oxidative stress in human 
endothelial cells (111). Since oxidative stress is involved in pulmonary 
hypertension (112,113), it is possible that both, an increase biosynthesis of 
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methylated arginines by upregulation of PRMTs and the reduction of metabolism 
by downregulation of DDAH are involved in the pathogenesis of pulmonary 
hypertension (Figure 33).  
 
 
Figure 33: Central role of ADMA, SDMA and DDAH in the pathogenesis of pulmonary 
hypertension. Schematic depiction of methyl arginine (ADMA and SDMA) elevation and their 
contribution to impaired NOS activity and its substrate (L-arginine) depletion that subsequently 
leads to reduced NO production, an underlying mechanism responsible for the pathogenesis of 
PAH. This elevation as evidenced by our experiments is due to both increased dimethylation and 
decreased expression of ADMA metabolizing enzyme, DDAH. The molecular mechanisms 
underlying DDAH suppression may include pro-inflammatory cytokines, TNF-  and IFNγ (Author's 
Slide).  
 
Most impressively, corresponding changes in dimethylarginines were also 
encountered in the human system: patients with IPAH displayed significantly 
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enhanced plasma and tissue ADMA and SDMA levels, and lung tissue DDAH2 
was markedly reduced on both the mRNA and protein level, in line with 
immunohistochemical findings. This consistency of results between the 
experimental model and the human disease strongly suggests that changes in 
dimethylarginine regulation may be of major importance for endothelial 
dysfunction in pulmonary hypertension. 
Besides the NO pathway, corresponding changes in dimetylarginines may 
influence various vasoactive mediator pathways, as suggested by previous 
findings. A positive correlation between plasma ADMA levels and endothelin 
(known to be a potent vasoconstrictor and mitogen), was found in various 
disorders of endothelial dysfunction. In denuded vessel endothelium an 
accumulation of endogenous NOS inhibitors (L-NMMA and ADMA) was 
accompanied by an increased endothelin-1 content within the vessel wall (114). 
Ohnishi et al demonstrated that ET-1 inhibits NO-mediated vasodilation in part 
via increased ADMA production in chronic heart failure (CHF). Furthermore, 
administration of an ET (A) receptor antagonist can prevent this increase in 
plasma ADMA levels, and also the increase in peripheral vascular resistance 
observed in these patients (115). Piatti et al. suggest that acute intravenous L-
arginine infusion in patients with angina pectoris decreases endothelin-1 levels 
and improves endothelial function (116). However, the influence of non selective 
or selective ET receptor antagonist treatment on endogenous dimethyl arginines 
(ADMA, SDMA), in the context of PAH, has not yet been addressed in detail. 
 
Future studies have to address the question whether enhanced supply with L-
arginine may overcome increases in dimethylarginine levels. Studies with L-
arginine supplementation for treatment of experimental or clinical pulmonary 
hypertension have provided controversial results. First, L-arginine analogues 
SDMA and ADMA, compete with L-arginine for intracellular uptake, but also drive 
out the intracellular L-arginine (80). Therefore, we believe that the huge increase 
of ADMA and SDMA, observed in our study (in both human and rat MCT model 
of PH) may competes with L-arginine uptake which results in a substantial 
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substrate depletion even when provided extracellularly. Second, increased levels 
of ADMA, the endogenous NOS inhibitor, may also “uncouple” endothelial NOS 
(84). In such conditions, molecular oxygen becomes the substrate for electron 
transfer rather than L-arginine, thereby blocking or inhibiting the access of 
intracellular L-arginine to NOS. Subsequently, endothelial NOS generates 
superoxide anion, increases oxidative stress, attenuates NO bioactivity, and 
induces additional endothelial dysfunction. Third, L-arginine may not be useful in 
later stages of pulmonary hypertension, in which cytokine- or lipid-induced 
instability and/or reduced transcription of NOS may decrease its expression. On 
the other hand, L-arginine supplementation showed beneficial effects on 
hemodynamics in patients with primary, secondary and precapillary pulmonary 
hypertension (56,103). Possible explanations for these short-term beneficial 
effects include nonenzymatic generation of NO from L-arginine, release of growth 
hormone or insulin, or effects at the level of the CAT proteins responsible for 
cellular uptake of L-arginine. Nevertheless, reversal of the effects of ADMA 
represents a persuasive mechanism. Another therapeutic strategy is 
manipulation of DDAH expression and function to foster dimethylarginine 
catabolism by DDAH overexpression or by existing therapies of pulmonary 
hypertension such as statins, ET receptor antagonist or prostacyclin analogues. 
This may represent new strategies for treatment of this enigmatic disease. 
 
In conclusion, we were able to demonstrate that enhanced dimethylarginine 
levels contribute to vascular abnormalities in severe pulmonary hypertension. 
Furthermore, suppression of endothelial DDAH2 expression and function 
represents an important underlying mechanism in the course of the disease.  
 
These findings are confirmed in a well-established animal model of pulmonary 
hypertension as well as in tissue and plasma of patients suffering from idiopathic 
pulmonary arterial hypertension. The current study might stimulate development 
of novel therapeutics that target the signaling pathway of endogenous NOS 
inhibitors and support the functional capacity of DDAH. 
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5.2 Tolafentrine increases nitric oxide synthesis in MCT induced pulmonary 
hypertension: a role for the induction of DDAH2 
Astonishingly, in our screening tolafentrine was identified as novel therapeutic 
that can target the signaling pathway of endogenous NOS inhibitors. Daily 
repetitive inhalations of tolafentrine, a combined PDE 3/4 inhibitor, to MCT-PAH 
rats restored DDAH expression and activity. Besides, it also improved the 
impairment of endothelium-dependent relaxation and normalized nitrite levels in 
MCT-induced pulmonary hypertensive rats. Furthermore, the inhalative therapy 
commenced during the development of pulmonary hypertension, 2 weeks after 
application of monocrotaline, improved pulmonary hemodynamics and reversed 
structural and molecular changes underlying MCT induced PAH in rats. 
 
The phosphodiesterases (PDEs) are a large family of intracellular enzymes that 
degrade cyclic nucleotides cAMP and cGMP (59,60). cAMP- PDEs, mainly PDE 
3 and 4 isoenzymes have been demonstrated as essential players co-regulating 
cAMP catabolism in many organs, including the lung, and were shown to be 
upregulated in experimental PAH models (117-119). Moreover, experimental 
evidence has suggested that combined phosphodiesterase (PDE) 3/4 inhibitors 
increase cyclic AMP levels within cells greater than inhibition of either isoenzyme 
alone (120). Because of cAMP potential for altering a variety of cellular 
responses, cAMP-PDEs are appealing targets for the treatment of PAH (121). 
cAMP-PDEs may become a very useful tool for the treatment of PAH. 
 
A recent study by our group showed that intravenous infusion of the combined 
selective PDE 3/4 inhibitor (tolafentrine) prevented the development of 
pulmonary hypertension and right ventricular hypertrophy in response to 
monocrotaline (122). However, the complexity and complications associated with 
the intravenous application of an agent exerting at the same time pulmonary and 
systemic vasodilation prompted us to evaluate the inhalative route of application 
in the present study. Moreover, the therapeutic potential of tolafentrine, and its 
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impact on molecular mechanisms closely linked with the structural wall changes 
were not addressed in the previous study. 
 
For the inhalation therapy, aimed to achieve a selective pulmonary vasodilation, 
a 15 fold lower dose compared with the intravenous route of application was 
employed (120µg/kg day versus 2mg/kg day). Even with such low dose, 
tolafentrine treatment drastically improved MCT-induced hemodynamic 
abnormalities: RVSP values were markedly lower than those before onset of 
treatment, and cardiac index as well as pulmonary vascular resistance was fully 
normalized. Accordingly, the right heart hypertrophy was found to be largely 
decreased, as were the structural changes of the lung vasculature evoked by 
monocrotaline treatment. To our knowledge, we were the first to demonstrate the 
efficacy of combined selective PDE 3/4 inhibition in prevent the development of 
pulmonary hypertension both with respect to hemodynamics and the structural 
remodeling of the lung vasculature. These most impressive beneficial effects of 
tolafentrine may in part be explained by cAMP-mediated inhibition of proliferation, 
cell cycle progression of PASMC (123,124). In one of our previous studies we 
showed that cAMP-PDEi mainly combined PDE 3/4 inhibitors prevents 
experimental induced PAH by anti-migratory and matrix (MMP) regulation 
properties. Those were mainly mediated by downregulation of gelatinases, 
MMP2 and MMP9 (122). 
 
Besides, we have shown for the first time that tolafentrine reverses endothelial 
dysfunction in chronic pulmonary hypertensive rats. This may be related to 
increased synthesis of endothelial NO, as evidenced by increased nitrite/nitrate 
levels. Consistent with the functional data, PDE3 and PDE4 were the major 
cAMP hydrolysis enzymes in intact endothelial cells and their role in lung 
inflammation and hyperpermeability of pulmonary endothelial monolayers, 
strongly suggests the protective role of combined PDE 3/4 inhibitors on vascular 
endothelial function (125-127).The mechanisms responsible for the cAMP 
enhancement mediated NO formation are not yet fully understood and may 
Discussion                                                                                                            77 
 
 
include both eNOS expression and activity modulation. Nevertheless, to date, no 
data are available regarding effects of cAMP on endogenous NOS inhibitors.  
Most interestingly, cAMP augmentation by PDE3/4 inhibition was shown to 
influence dimethylarginines levels. Tolafentrine treatment of MCT-PAH rats for 2 
weeks drastically reduced both ADMA and SDMA levels that were upregulated 
during development of MCT-induced PAH. Decreased ADMA levels can be partly 
explained by restored DDAH2 expression and activity mediated by tolafentrine. 
Because DDAH is a key regulator of endogenous ADMA levels, increased DDAH 
expression and activity may accelerate the degradation of endogenous ADMA, 
thereby enhancing the activity of eNOS and eventually augmenting the synthesis 
of NO. Clearly evidenced by our experiments, nitrite levels were near normalized 
to control values in tolafentrine treated pulmonary hypertensive rats (Figure 34). 
 
 
Figure 34: Tolafentrine: Augmentation of NO production in chronic pulmonary 
hypertensive rats. Schematic depiction of molecular mechanisms responsible for augmented 
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NO production by Tolafentrine. Tolafentrine, a combined PDE 3/4 inhibitor by increasing 
intracellular cAMP levels enhances NO production by modulating methyl arginine (ADMA and 
SDMA) concentrations, that were altered during progressive pulmonary hypertension. These 
modulatory effects as evidenced by our experiments are due to an upregulation of DDAH 
expression and activity (Author's Slide). 
 
Although we did not address the effects of tolafentrine on eNOS expression and 
activity, previous reports suggest that a rise in intracellular cAMP may activate 
endothelial NOS (eNOS) either directly or indirectly and evoke NO cGMP 
mediated relaxation (128,129). Chen et al. reported that eNOS is phosphorylated 
at Ser-1177 by protein kinase A that can be phosphorylated and activated by 
cAMP (130). Importantly, two recent studies by Fulton et al and Dimmeler et al 
found that eNOS is an efficient substrate for protein kinase Akt (PKB). PKB via 
activation PI3 kinase phosphorylates eNOS directly and thereby increases its 
activity (131,132). Further, Niwano K et al. showed that additional regulatory 
mechanisms control eNOS expression via cAMP signaling in vitro (133). Even 
though, the effect of cAMP on eNOS transcription in vivo remained speculative.  
Several anti-inflammatory molecules were already shown to reduce ADMA levels 
by reducing oxidative stress and subsequent enhancement of DDAH activity 
(134,135). But the results of two small studies of antioxidant vitamins have been 
negative or inconclusive, thereby cautioning to target DDAH enzyme expression. 
Our study identified combined PDE 3/4 inhibitor as one of the transcriptional 
modulator of DDAH2 other than all-trans-Retinoic Acid (109). In addition to 
transcriptional regulation, combined PDE 3/4 inhibitor by its potent anti-
inflammatory properties directly influences DDAH activity. Therefore, these two 
pathways together enhance the bioavailability of NO, improving the impairment of 
endothelium-dependent relaxation induced by MCT.  
In conclusion, combined PDE 3/4 inhibitors by increasing NO synthesis and 
bioactivity acutely reduces pulmonary pressures by its effects on vasoreactivity 
and chronically reduces the progression of disease-media hypertrophy, intimal 
hyperplasia, and thrombosis by elevating both NO and cAMP.  
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6. Summary 
 
Idiopathic pulmonary arterial hypertension (IPAH) is a progressive and life- 
limiting disorder which is associated with impaired bioactivity and/or synthesis of 
endogenous nitric oxide (NO). The mechanisms resulting in this impairment are 
multifactorial. Recently, the impact of endogenous NO-synthase inhibitors such 
as dimethylarginines (ADMA and SDMA) has come into the focus of attention for 
various endothelial dysfunction associated cardiovascular disorders. As current 
evidence strongly suggests a central role for endothelial dysfunction in the 
initiation and progression of pulmonary arterial hypertension (PAH), the plausible 
role of dimethylarginines is speculated in this disease. Hence forth, the present 
study was undertaken to investigate the potential role of dimethylarginines in the 
course of chronic pulmonary hypertension. If this speculation was to be proven, 
further studies aimed to delineate the precise mechanisms responsible for these 
alteration including biosynthesis and metabolism of these mediators. These 
studies were performed mainly on plasma and lung tissues obtained from both 
IPAH patients and monocrotaline induced pulmonary hypertensive (MCT-PAH) 
rats.   
Interestingly, in both MCT-PAH rats and patients suffering from IPAH (NYHA 
class III and IV), a marked increase in plasma ADMA and SDMA levels 
compared to their healthy counterparts was observed. These findings were nicely 
corroborated by increased biosynthesis as evidenced by high expression of 
asymmetric and symmetric dimethylated arginine proteins in lung tissues from 
patients suffering from PAH as well as from MCT-PAH rats. Moreover, the main 
endothelial ADMA metabolizing enzyme, DDAH2, was found to be drastically 
reduced in IPAH patients and MCT-PAH rat tissue, at both the mRNA and the 
protein level with no significant changes in DDAH1 expression. The consistency 
of results seen in human disease and in an established experimental animal 
model of pulmonary hypertension strongly suggests that changes in 
dimethylarginine regulation may contribute considerably to the course of the 
disease. The current study also suggests that novel therapeutics that target the 
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signaling pathway of endogenous NOS inhibitors and promote the functional 
capacity of DDAH2 would be beneficial for the treatment of IPAH. 
Interestingly, we identified the phosphodiesterase 3/4 inhibitor, tolafentrine as the 
first transcriptional modulator of DDAH2 in chronic MCT-PAH rats. Daily 
repetitive inhalation of tolafentrine by augmenting intracellular cAMP levels 
restored DDAH expression, activity and nitrite levels that were decreased during 
the development of MCT-induced PAH. DDAH2 activity restoration was 
functionally evidenced by near normalized ADMA plasma levels in tolafentrine 
treated MCT-PAH rats. Furthermore, we also observed a decreased SDMA 
levels in tolafentrine treated animals, although the mechanisms responsible for 
this change is not yet clear. Finally, as a regulator of endogenous NOS inhibitors, 
tolafentrine treatment drastically improved MCT-induced hemodynamic 
abnormalities and reversed structural and molecular changes underlying MCT 
induced PAH in rats in the current study. 
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7. Zusammenfassung 
 
Die chronische pulmonalarterielle Hypertonie (PAH) hat eine schlechte Prognose 
und betrifft ein großes und zudem wachsendes Patientenkollektiv. Als Auslöser 
dieser Erkrankung gelten Hypoxie, Entzündung, Thromboembolie und 
Hyperzirkulation. Ein wesentlicher Pathomechanismus ist die Verschiebung des 
komplexen Gleichgewichts vasokonstriktiver und vasodilatativer Mediatoren in 
Richtung der Vasokonstriktoren, verbunden mit verschiedenen strukturellen 
Veränderungen an den Pulmonalarterien. Der Mangel an Vasodilatatoren wie 
Stickstoffmonoxid und Prostazyklin und die Überexpression von 
Vasokonstriktoren, wie Endothelin und Thromboxan, tragen allerdings nicht nur 
zum erhöhten vaskulären Tonus bei, sondern sind auch maßgeblich am Verlust 
der physiologischen flussabhängigen Vasodilatation beteiligt. Insbesondere die 
Stickstoffmonoxidsynthase (NOS) spielt eine zentrale Rolle in der 
Pathophysiologie dieser pulmonalvaskulären Dysfunktion. Kürzlich konnte 
gezeigt werden, dass bei verschiedenen kardiovaskulären Erkrankungen erhöhte 
Konzentrationen endogener Hemmstoffe (symmetrisch dimethyliertes Arginin 
(SDMA) oder asymmetrisch dimethyliertes Arginin (ADMA)) der NOS messbar 
sind. 
In der vorliegenden Arbeit wurden zunächst Untersuchungen an Plasma und 
Lungengewebe von Patienten mit idiopathischer pulmonalarterieller Hypertonie 
(IPAH) und Ratten mit experimenteller pulmonaler Hypertonie durch Injektion von 
Monocrotalin (MCT-PAH) untersucht. Dabei wurde erstbeschreibend gefunden, 
dass in IPAH Patienten (NYHA Klasse III und IV) und MCT-PAH Ratten die 
Plasmaspiegel der endogenen NOS-Hemmstoffe ADMA und SDMA im Vergleich 
zu Kontrollen drastisch erhöht sind. Die erhöhte Biosynthese von ADMA und 
SDMA wurde im Gewebe durch immunhistochemische und biochemische 
Untersuchungen nachgewiesen. Es konnte weiterhin gezeigt werden, dass das 
ADMA metabolisierende Enzym Dimethylarginin-Dimethylaminohydrolase 
(DDAH2) hochsignifikant bei klinischer und experimenteller pulmonaler 
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Hypertonie herabreguliert ist. Durch die verringerte Aktivität des Enzyms wird die 
gefäßengstellende Wirkung des ADMA verstärkt und verlängert.  
Die transkriptorische Modulation der DDAH2 Expression gelang mit Hilfe des 
dual-selektiven Phosphodiesterase Inhibitors Tolafentrin, welcher nach 
chronischer Applikation bei experimenteller PAH eine Hochregulation der DDAH2 
und dadurch Reduktion der Plasmaspiegel von ADMA induzierte. Durch 
Erhöhung der intrazellulären cAMP Spiegel wurde die DDAH2-Expression 
(gezeigt durch immunhistochemische und biochemische Methoden) sowie -
Aktivität angehoben. Diese pharmakologische Hochregulation der DDAH2 führte 
neben der Reduktion der Plasmaspiegel von ADMA und SDMA auch zu 
Verbesserungen der Hämodynamik und zu einer deutlichen Verbesserung der 
strukturellen Gefäßveränderungen. Zusammenfassend konnte erstmalig gezeigt 
werden, dass endogene Hemmstoffe der NO-Synthase bei pulmonalarterieller 
Hypertonie erhöht sind, was durch eine erhöhte Synthese im Lungengewebe, 
aber auch reduzierten Abbau durch die im Gefäß herunterregulierte DDAH2 
erklärt werden kann. Gleichzeitig gelang es in der vorliegenden Arbeit, durch 
eine pharmakologische Intervention dieses Schlüsselenzym im kardiopulmonalen 
Gefäßsystem hoch zu regulieren, was in dem experimentellen Modell des 
Lungenhochdrucks zu einer Normalisierung der hämodynamischen und 
histologischen Veränderungen führte.  
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